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INTRODUCTION 
Tablets 
Tablets may be defined as solid pharmaceutical dosage forms containing drug 
substances with or without suitable diluents and prepared either by compression or 
molding methods. They have been in widespread use since the latter part of the 19
th 
century and their popularity continues. The term compressed tablet is believed to have 
been first used by “JOHN WYETH and Brother of PHILADELPHIN”. During the same 
period molded tablets were introduced to be used as Hypodermic tablets for injections.  
Tablets remain popular as oral dosage form because of the advantages, afforded 
both to the manufacturer [e.g.: simplicity & economy of preparation, stability and 
convenience in packing, shipping, and dispensing] and the patient [e.g.: accuracy of 
dosage, compactness, post ability, blandness of taste and ease of administration. 
Although tablets are more frequently discoid in shape, they also may be round, 
oval, oblong, cylindrical or triangular. They may differ greatly in size and weight 
depending on the amount of drug substance present and the intended method of 
administration. 
Properties of tablets 
  The attributes of an acceptable tablet are as follows: 
 The tablet must be sufficiently strong and resistance to shock and abrasion and to 
withstand handling during manufacturing, packaging, shipping and use. Hardness 
and friability tests measure this property. 
 Tablet must be uniform in weight and in drug content of the individual tablet. 
This is measured by the weight variation and content uniformity tests. 
 The drug content of the tablet must be bioavailable. This property is measured by 
the dissolution test. Accurate bioavailability can be obtained from the drug levels 
of the drug after its administration. 
 Tablets must be elegant in appearance and must have characteristic shape, color 
and other markings necessary to identify the product. 
 Tablets must retain all these functional attributes, which include drug stability and 
efficacy. 
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Advantages of Tablets: 
 They are easy to be administered 
 They offer the greater capabilities of all oral dosage forms for the greatest dose 
precision and the least content variability. 
 Their cost is lowest of all oral dosage forms. 
 They are the lightest and most compact of all oral dosage forms. 
 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed 
punch face. 
 They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
 They may provide the greatest ease of swallowing with the least tendency for 
“hang-up” above the stomach.  
 They lend themselves to certain special release profile products, such as enteric or 
delayed release products. 
 They are better suited to large-scale production than other unit oral forms. 
 They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms.  
 One of the major advantages of tablet over capsules is that the tablet is essentially 
“tamperproof dosage form”. 
 
Disadvantages of Tablets: 
 Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low-density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, or any combination of these features may be difficult or impossible to 
zormulate and manufacture as a tablet that will still provide adequate or full drug 
bioavailability. 
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 Bitter tasting drugs, drugs with objectionable odor or drugs that the sensitive to 
oxygen or atmosphere moisture may require encapsulation or a special type of 
coating with may increase the most of the finished tablets.   
 A major disadvantage of capsules over tablets is their higher cost. 
 
Types of tablets 
Tablets are classified according to their route of administration or function. The 
following are the 5 main classification groups: 
 Tablets ingested orally  
1. Compressed tablets 
2. Multiple compressed tablets 
3. Multilayered tablets 
4. Sustained action tablets 
5. Enteric coated tablets 
6. Sugar coated tablets 
7. Film coated tablets 
8. Chewable tablets 
 Tablets used in the oral cavity 
1. Buccal tablets 
2. Sublingual tablets 
3. Lozenge tablets and torches   
4. Dental cones 
 Tablets administered by other routes 
1. Implantation tablets 
2. Vaginal tablets 
 Tablets used to prepare solutions  
1. Effervescent tablets 
 Molded tablets or tablet triturates (TT) 
1. Dispensing tablets (DT) 
2. Hypodermic tablets (HT) 
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Compressed tablets:  
 These tablets are uncoated and made by compression of granules. These tablets 
are usually intended to provide rapid disintegration and drug release. These tablets  
 contain water-soluble drugs, which after swallowing get disintegrated in the 
stomach, and its drug contents are absorbed in the gastrointestinal tract and distribute in 
the whole body.  
 
Multiple compressed tablets (MCT):  
These tablets are prepared to separate physically or chemically incompatible 
ingredients or to produce repeat action prolonged action products. To avoid 
incompatibility, the ingredients of the formulation except the incompatible materials are 
compressed into a tablet then incompatible substances along with necessary excipients 
are compressed tablet.  
 
Multilayered tablets:  
These tablets consist of two or more layer of materials compressed successively in 
the same tablets. The color of each layer may be the same or different. The tablets having 
layers of different colors are known as “multicolored tablets”. 
 
Sustained action tablets:  
These tablets are used to get a sustained action of medicament. These tablets 
when taken orally release the medicament in a sufficient quantity as and when required 
maintaining the maximum effective concentration of the drug in the blood through out 
the period of treatment. 
 
Enteric-coated tablets (ECT): 
  These are compressed tablets meant for administration by swallowing and are 
designed to bypass the stomach and get disintegrated in the intestine only. These tablets 
are made to release the drug undiluted and in the highest concentration possible within 
the intestine. e.g.: tablets containing antihelmentics and amoebicides. 
 
Sugar coated tablets (SCT):  
The compressed tablets having a sugar coating are called “sugar coated tablets”. 
Such coatings may be colored and are beneficial in covering up drug substances 
processing objectionable tastes or odors and protecting materials sensitive to oxidation. 
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Film coated tablets (FCT):  
These are compressed tablets that are covered with a thin layer or a film of water-
soluble material. A number of polymeric substances with film-forming properties may be 
used. Film coating imparts the same general characteristics as sugar coating, with the 
added advantage of greatly reduced time period required for the coating operation and 
reduced thickness of coating, these compressed tablets having some polymer substance, 
such as hydroxy propyl cellulose, hydroxy propyl methylcellulose and ethyl cellulose.   
 
Chewable tablets:  
These tablets are to be chewed in the mouth and broken into small pieces. In this 
way, the disintegration time is reduced and the rate of absorption of he medicament is 
increased. e.g.: aluminum hydroxide tablets, and phenolphthalein tablets. 
 
Buccal tablets: 
  These tablets are to be placed in the buccal pouch or between the gums and lips or 
cheek where they dissolve or disintegrate slowly and are absorbed directly without 
passing into the alimentary canal. e.g.: tablets of ethisterone 
 
Sublingual tablets:  
These tablets are to be placed under the tongue where they dissolve or disintegrate 
quickly and are absorbed directly without passing into GIT. E.g.: tablets of glyceryl 
trinities. 
 
Lozenges and torches:  
These tablets are designed to exert local effect in the mouth or throat. These 
tablets are commonly used to treat sore throat or to control coughing in common cold. 
They may contain local anaesthetics antiseptic, antibacterial agents, astringent and 
antitussives. 
 
Dental cones:   
  These are relatively minor compressed tablets meant for placing them in the 
empty socket after tooth extraction. They prevent the multiplication of bacteria in the 
socket following such extraction by using slow releasing antibacterial compounds or to 
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reduce bleeding by containing the astringent. These cones generally get dissolved in 20 to 
40 min time. 
Implantation tablets:  
These tablets are placed under the skin or inserted subcutaneous by means of minor 
surgical operation and are slowly absorbed. These implants must be sterile and should be 
packed individually in sterile condition. Implants are mainly used for administration of 
hormones such as testosterone, and deoxycorticosterone etc. 
 
Vaginal tablets: 
  These tablets are meant to dissolve slowly in the vaginal cavity. These tablets are 
typically ovoid or pear shaped to facilitate retention in the vagina. This tablet form is 
used to release steroids, antibacterial agents, antiseptics or astringents to treat vaginal 
infections. 
 
Effervescent tablets:   
In addition to the drug substance, these contain sodium bicarbonate and an 
organic acid such as tartaric acid or citric. In the presence of water, these additives react, 
liberating carbon dioxide that acts as disintegrator and produces effervescence. Except for 
small quantities of lubricants present, effervescent tablets are soluble. 
 
Tablet triturates  
Tablet triturates usually are made from moist material, using a triturate mold that 
gives them the shape of cut sections of cylinder. Such tablets must be completely and 
rapidly soluble. The problem arising from the compression of these tablets is the failure 
to find a lubricant that is completely water-soluble. 
 
Dispensing tablets:  
These tablets provide a convenient quality of potent drug that can be incorporated 
readily in to powders and liquids, thus circumventing the necessity to weigh small 
quantities. These tablets are supplied primarily as a convenience for extemporaneous 
compounding and should never be dispensed as a dosage form. 
Hypodermic tablets: 
 Hypodermic tablets are soft, readily soluble tablets and originally were used for 
the preparation of solutions to be injected. Since stable parenteral solutions are now 
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available for most new drug substances, there is no justification for the hypodermic 
tablets for injection. Their use in this manner should be discouraged, since the resulting 
solutions are not sterile. Large quantities of these tablets continue to be made, but for oral 
administration. No hypodermic tablets ever have been recognized by the official 
compendia. 
Tablets and hard gelatin capsules constitute a major portion of drug delivery 
systems that are currently available. However, many patient groups such as the elderly, 
children and patients who are mentally retarded, uncooperative, nauseated, or on reduced-
liquid-intake diets have difficulty in swallowing these dosage forms. Elderly patients may 
find the administration of these dosage forms particularly difficult because many of them 
are required to consume medicines on a regular basis to maintain their quality of life. 
Children also may have difficulty ingesting these dosage forms because of their 
underdeveloped muscular and nervous systems. Swallowing conventional tablets can be 
further hindered by conditions such as allergic reactions, and episodes of coughing
1
. 
  
 The aforementioned problems can be solved by developing rapidly disintegrating 
and dissolving tablet dosage forms for oral administration because they dissolve in saliva 
and do not require water for swallowing. Oral disintegrating tablets are also called as 
‘mouth dissolving tablets’, ‘orodispersible tablets’, quick disintegrating tablets, rapid 
dissolving tablets, porous tablets and rapimelts
2
.  
 
Recently orally disintegrating tablet terminology has been approved by United 
States Pharmacopoeias, Centre for Drug Evaluation and Research (CDER).  
 
US FDA defined orally disintegrating tablet as ‘A solid dosage form containing 
medicinal substances, which disintegrates rapidly, usually within a matter of seconds, 
when placed upon the tongue’. Recently European pharmacopoeia also adopted the term 
‘orodispersible tablet’ as a tablet that is to be placed in the mouth where it disperses 
rapidly before swallowing
3
. Despite various terminologies used, orally disintegrating 
tablets are here to offer unique form of drug delivery with many advantages over the 
conventional dosage forms. 
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ORALLY DISINTEGRATE TABLETS:  
 
Oral drug delivery remains the preferred route for administration of various drugs. 
Recent developments in the technology have prompted scientists to develop orally 
disintegrate tablets (ODT) with improved patient compliance and convenience. ODTs are 
solid unit dosage forms, which disintegrate or dissolve rapidly in the mouth without the 
need of chewing and water. It is particularly meant for people who have difficulty in 
swallowing conventional tablets and capsules.  It has been reported that Dysphasia 
(difficulty in swallowing) is common among all age groups and more specific with 
pediatric and geriatric populations along with institutionalized patients and patients with 
nausea, vomiting, and motion sickness complications. ODTs with good taste and flavor 
increase the acceptability of bitter drugs by various groups of population
1
. 
  
 Orally disintegrating tablets are also called as orodispersible tablets, quick 
disintegrating tablets, mouth dissolving tablets, fast disintegrating tablets, fast dissolving 
tablets, rapid dissolving tablets, porous tablets and rapimelts. However, of all the above 
terms, United States pharmacopoeia (USP) approved these dosage forms as ODTs. 
Recently, European Pharmacopoeia has used the term orodispersible tablets that disperse 
readily and within 3 min in mouth before swallowing. 
  
 USFDA defined ODT as “A solid dosage form containing medical substance or 
active ingredient which disintegrates rapidly usually within a matter of seconds when 
placed upon the tongue”. The disintegration time for ODTs generally ranges from several 
seconds to about a minute. 
 
Typically a dispersible tablet is dispersed in about 5-15 ml of water (e.g. in a 
tablespoonful or a glass of water) and the resulting dispersion is administered to the 
patient. However, they can also be placed directly on the tongue and sucked. Dispersible 
tablets are required to disintegrate within 3 mins in water at 15-25°C. Also the dispersion 
produced from a dispersible tablet should pass through a sieve screen with a nominal 
mesh aperture of 710 microns. The dispersion properties of dispersible tablets can be 
facilitated by the inclusion of an acid/base couple in which the base liberates carbon 
dioxide when the components of the couple are dissolved in water. 
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 Ideal characteristics of dispersible tablets 
 They require water or other liquid at the time of administration. 
 Should easily disintegrate and dissolve. 
 Mask or overcome unacceptable taste of drug. 
 They should have high drug loading. 
 They should have pleasant feel in the mouth. 
 They should have low sensitivity against environmental conditions like moisture, 
temperature etc. 
 Ease of administration for patients who are mentally ill, disabled and 
uncooperative. 
 Should be portable without fragility concern. 
 They should be manufactured using conventional tablet processing and packaging 
equipment at low cost. 
Special features of dispersible tablets 
 Dispersible tablets are not intended to be chewed or swallowed whole. They 
should not be dispersed in carbonated drinks or milk due to foaming or slow 
dispersion. The purpose of dispersible tablet is to provide a unit dosage form of 
medication which can be easily administered to infants and children or to elderly, 
who may have difficulty swallowing a tablet intact. 
 Advantages of dispersible tablets 
 They are particularly suitable both for elderly persons with swallowing difficulties 
and for children.  
 Rapid disintegration and absorption of drug, which will produce quick onset on 
action. 
 Certain dispersible tablets can also be divided.  
 The bitter taste of the active substance must be masked in advance.   
 Owing to the number of possible applications, the patient compliance is 
improved.  
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 These are convenient to carry, easy to manufacture and more stable. 
 Quick absorption from the gastrointestinal tract improves bioavailability and 
reduces unwanted effects caused by the drug. e.g. gastrointestinal irritation caused 
by nonsteroidal anti inflammatory drugs. 
 New business opportunities like product differentiation, line extension and life 
cycle management. Exclusivity of product promotion. 
 Although chewable tablets have been on the market for some time, they are not 
same as the new dispersible tablets. Patients for whom chewing is difficult or 
painful can use these new tablets easily. Dispersible tablets can be used easily in 
children who have lost their primary teeth, but do not have full use of their 
permanent teeth. 
Limitation of dispersible tablets 
 One common limitation of these formulations is settling of the insoluble solids at 
the bottom or sides of container of the prepared dispersion, which may lead to a 
loss of part of the drug during administration, resulting in suboptimal dosing. 
 Disadvantages of dispersible tablets 
 Most dispersible tablets lack the mechanical strength common to traditional 
tablets. Many products are very light weight and fragile requiring them to be 
individually packaged. Patients should be advised not to push these tablets 
through the foil film, but instead, peel the film back to release the fast dissolving 
tablet. 
 Due to the formulation of dispersible tablets which also more susceptible to 
degradation via temperature and humidity. Some of the newest dispersible tablet 
formulations are dispensed in a conventional stock bottle. Pharmacists are advised 
to take care when dispensing such formulations to ensure they are exposed to high 
levels of moisture or humidity. Excess handling of tablets can introduce enough 
moisture to initiate dissolution of the tablet matrix. 
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Developmental challenges in dispersible drug delivery 
 Ease of administration 
Fast Dissolving Delivery Systems are easy to administer and handle hence, leads 
to better patient compliance. Usually, elderly people and pediatrics experience 
difficulty in swallowing the conventional dosage forms (tablets, capsules, 
solutions and suspensions) because of tremors of extremities and dysphasia. Fast 
Dissolving Delivery Systems may offer a solution for these problems.  
 Taste of the active ingredient 
Some drugs have relatively no taste, and simply adding a suitable flavor can hide 
any unpleasant sensation. However, most drugs do require taste masking if they 
are to be incorporated into dispersible formulations. Numerous methods exist to 
achieve this, including simple wet granulation or roller compression with other 
excipients to minimize the presented surface area of the drug. Spray drying can 
also be employed to shroud the drug. If further taste masking is needed, the 
resultant particle can be sealed with a suitable coating material (like 
hydroxypropyl methyl cellulose, ethylcellulose, methacrylate and 
polyvinylpyrollidone). The choice of coating material will determine the 
mechanism of taste masking. In addition, the quantity of coat applied, how it is 
applied, and where other excipients are included in the coating will all affect the 
quality of taste masking. 
Cyclodextrins (cyclic linked oligosaccharides) have been shown to prove some 
measure of taste masking by trapping the drug within the cyclic structure long 
enough to render initial dissolution. Other taste masking methods namely coating 
methods including electrochemical, hot melt and supercritical fluids. 
Encapsulation using coacervation has also been employed to encapsulate certain 
drugs. 
 Dose 
Molecules requiring high doses present challenges to development of dispersible 
dosage forms: 1) Taste masking of active ingredient, 2) mouth-feel or grittiness 
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and 3) tablet size. These challenges are not unrelated because most drugs will 
require taste masking. It depends on the degree of bitterness relative to the dose of 
the drug, which will in turn effect the final tablet size. As mentioned previously, 
drug may require coating, which will result in an increase in the particle size. The 
extent to which this increase will affect the mouth feel and tablet size will depend 
on the dose of the drug and the amount of coating material required masking its 
taste. 
 
 Hygroscopicity 
Several fast dissolving tablets are hygroscopic and cannot maintain physical 
integrity under normal conditions of temperature and humidity. Hence they need 
protection from humidity that calls for specialized product package. 
 
 Friability 
In order to allow dispersible tablets to disintegrate rapidly in the mouth, they are 
made of either very porous or soft molded matrices or compressed into tablets 
with low compression force, which makes the tablet friable and/or brittle which 
are difficult to handle, often require specialized peel-off blister packing. 
Mouth feel 
 Mouth feel is critical, and patients should receive a product that feels 
pleasant. Any large particles from the disintegrating tablet that are insoluble 
or slowly soluble in saliva would lead to an unpleasant gritty feeling. This can 
be overcome by keeping the majority of the particles below the detectable size 
limit. In some cases, certain flavors can imbibe an improved mouth feel 
perception, resulting in a product that is perceived as being less gritty, even if 
the only change is the flavor. Effervescence can be added to aid disintegration 
and improve mouth feel by reducing the “dryness” of a product. 
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SIGNIFICANCE
2
: 
 ODTs offer all advantages of solid dosage forms along with special advantages, 
include: 
 As ODTs are unit solid dosage forms, they provide good stability, accurate 
dosing, easy manufacturing, small packaging size, and easy to handle by patients. 
Rapid disintegration of tablet results in quick dissolution and rapid absorption which 
provide rapid onset of action. 
 Medication as bitter pill has changed by excellent mouth feel property produced 
by use of flavors and sweeteners in ODTs. 
Bioavailability of drugs that are absorbed from mouth, pharynx, and esophagus is 
increased. 
 Pre-gastric absorption of drugs avoids hepatic metabolism, which reduces the 
dose and increases the bio-availability. 
 
Selection of ODT drug candidates
3 
Several factors must be considered when selecting drug candidates for delivery as 
ODT dosage forms. In general, an ODT is formulated as a bioequivalent line extension of 
an existing oral dosage form. Under these circumstances, it is assumed that the absorption 
of a drug molecule from the ODT occurs in the post gastric GIT segments, similar to the 
conventional oral dosage form. 
 
It is possible that these differences may, in part, be attributed to the drug 
molecule, formulation, or a combination of both. If significantly higher plasma levels and 
systemic exposure have been observed, pregastric absorption leading to the avoidance of 
first-pass metabolism may play an important role. This situation may have implications 
for drug safety and efficacy, which may need to be addressed and assessed in a marketing 
application for an ODT (13). For example, safety profiles may be improved for drugs that 
produce significant amounts of toxic metabolites mediated by first-pass liver metabolism 
and gastric metabolism and for drugs that have a substantial fraction of absorption in the 
oral cavity and segments of the pregastric GIT.  
The ideal characteristics of a drug for dissolution in the mouth and pregastric absorption 
from an ODT include:  
Introduction 
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           14 
 
1. No bitter taste; 
2. Dose lower than 20 mg; 
3. Small to moderate molecular weight; 
4. Good solubility in water and saliva; 
5. Partially nonionized at the oral cavity's ph; 
6. Ability to diffuse and partition into the epithelium of the 
upper git (log p >1, or preferably >2);  
7. Ability to permeate oral mucosal tissue (15). 
8. In contrast, the following characteristics may render a drug 
unsuitable for delivery as an odt:  
9. Short half-life and frequent dosing; 
10. Very bitter or otherwise unacceptable taste because taste 
masking cannot be achieved; 
11. Require controlled or sustained release. 
12. The drug dose must be lower than 400 mg for insoluble drugs 
and less than 60 mg for soluble drugs (because they dissolve 
quickly, odts cannot provide controlled or sustained release, 
except those that contain slow-dissolving, microparticulate-
coated drugs, which quickly disperse and are swallowed.  
 
Oral routes of drug absorption: 
There are two permeation pathways for passive drug transport across the oral mucosa: 
1. Paracelluloar and 
2. Transcellular routes. 
Descriptions of orally disintegrating dosage forms
3
: 
Possible benefits of Orally disintegrating tablet drugs. 
 Clinical 
1. Improved drug absorption 
2. Faster onset of  action 
3. Minimized first-pass effect 
4. Improved Bioavailability 
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 Medical 
1. Better taste, no water needed 
2. Improved stability because of unit-dose packaging 
3. Manufactured with common process and conventional equipment 
 
Orally disintegrating tablet manufacturers and technology characteristics: 
Technology 
In vitro 
Disintegra
tion 
Times 
Tablet 
hardness and 
Robustness 
Packaging 
Drug-
loading 
dose(mg) 
Marketed 
products 
worldwide 
Advatab (Eurand) 15-30 Hard, robust 
Bottles or blister 
pack 
<700 2 
DuraSolv (CIMA 
Labs) 
<30 Hard, robust 
Bottles or blister 
pack 
<500 3 
FlashDose (Biovail) 5-15 Soft, friable Blister pack <600 1 
FlashTab (ethypharm 
SA) 
30-60 
Relatively 
durable 
Blister pack <650 3 
Lyoc (Cephalon) <10 Soft, friable Blister pack <1000 6 
OraQuick 
(KVPharmaceuticals) 
<20 
Relatively 
durable 
Bottles or blister 
pack 
<500 1 
OraSolv (CIMA Labs) <30 Soft, fragile Blister pack <750 3 
SATAB (Sato) <10 
Relatively 
durable 
Blister pack <600 7 
WOWTAB 
(Yamanouchi) 
<30 
Relatively 
durable 
Bottles or blister 
pack 
<500 14 
Zydis (Cardinal 
Health) 
3-5 Very fragile Blister pack <400 15 
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Techniques used in the formulation of dispersible tablets 
 The performance of dispersible tablets depends on the technology used in their   
manufacture. The orally disintegrating property of the tablet is attributable to a quick 
ingress of water into the tablet matrix, which creates porous structure of the tablet matrix, 
which creates porous structure and results in rapid disintegration. Hence, the basic 
approaches to develop dispersible tablets include maximizing the porous structure of the 
tablet matrix, incorporating the appropriate disintegrating agent and using highly water-
soluble excipients in the formulation. 
Following technologies have been used by various researchers to prepare fast 
disintegrating tablets: 
 Freeze-drying or lyophilization  
 Tablet Molding  
 Direct compression  
 Wet granulation 
 Spray drying  
 Sublimation  
 Taste masking 
 Mass extrusion  
Freeze-Drying or lyophilization 
 Freeze drying is the process in which water is subjected from the product after it 
is frozen. This technique creates an amorphous porous structure that can dissolve rapidly. 
Commonly used excipients with their uses and examples employed in formulation of 
dispersible tablets using Freeze-drying are listed below in the following table. A typical 
procedure involved in the formulation of dispersible tablets using this technique is 
mentioned here. The active drug was dissolved or dispersed in an aqueous solution of a 
carrier/polymer. The mixture dosed by weight and poured in the wells of the preformed 
blister packs. The trays holding the blister packs are passed through liquid nitrogen 
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freezing tunnel to freeze the drug solution or dispersion, and then the frozen blister packs 
are placed in refrigerated cabinets to continue the freeze-drying. After freeze-frying the 
aluminum foil backing is applied on a blister sealing machine. Finally the blisters are 
packaged and shipped. 
 Excipients and their uses in Freeze drying technique 
Excipients Use Examples 
Polymer Strength and rigidity Gelatin, alginate and dextrin 
Polysaccharides 
Crystallinity, hardness and 
palatability 
Mannitol and sorbitol 
Collapse protectants Prevents shrinking Glycerin 
Flocculating agents Uniform dispersion Xanthan gum and acacia 
Preservatives 
Prevent microbial and fungal 
growth 
Parabens 
Permeation enhancer Transmucosal permeability Sodium lauryl sulphate 
pH adjusters Chemical stability 
Citric acid and sodium 
hydroxide 
Flavors and sweeteners Patient compliance ------- 
Water Porous unit formation ------- 
 
 The freeze-drying technique has demonstrated improved absorption and increase 
in bioavailability. The Zydis formulation consist of a drug physically trapped in a water-
soluble matrix (saccharine mixture and polymer), which is freeze dried to produce a 
product that dissolves rapidly when placed in mouth. The ideal candidate for Zydis 
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technology should be chemically stable and water insoluble and particle size preferably 
less than 59 mm. Water soluble drugs might form eutectic mixtures and not freeze 
adequately, so dose is limited to 60 mg and the maximum drug limit is 400 mg or water 
insoluble drug as large particle sizes might present sedimentation problems during 
manufacture. The major disadvantage of lyophilization technique are that it is expensive 
and time consuming; fragility makes conventional packaging unsuitable for these 
products and poor stability under stressed conditions. 
Tablet Molding 
 The preparation of dispersible tablets using molding technology employs water-
soluble ingredients so that the tablet dissolves completely and rapidly. The active 
ingredients in most cases are absorbed through the mucosal lining of the mouth. Molding 
process is of two types i.e., solvent method and heat method. Solvent method involves 
moistening the powder blend with a hydro alcoholic solvent followed by compression at 
low pressures in molded plates to form a wetted mass (compression molding). The 
solvent then removed by air-drying. The tablets manufactured in this manner are less 
hastens dissolved. The heat molding process involves preparation of a suspension that 
contains a drug, agar and sugar (e.g. Mannitol or Lactose) and pouring the suspension in 
the blister packing wells, solidifying the agar at room temperature to form a jelly and 
drying at 30°C under vacuum. The mechanical strength of molded strength of the tablets, 
need to be incorporated. Taste masking is an added problem for this technology. 
Direct compression 
 It is the convenient way to manufacture tablets. Conventional equipment, 
commonly available excipients and a limited number of processing steps are involved in 
direct compression. Also high doses can be accommodated and final weight of tablet can 
easily exceed that of other production methods. This technique can now be applied to 
dispersible tablets because of the availability of improved tablet excipients, especially  
1) Tablet disintegrants  
2) Sugar-based excipients.  
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1) Addition of disintegrants: Addition of disintegrants in fast dissolving tablets, leads to 
quick disintegration of tablets and hence improves dissolution. In many fast dissolving 
tablet technologies based on direct compression, the disintegrants principally affect the 
rate of disintegration and hence the dissolution. The introduction so-called 
superdisintegrants and a better understanding of their properties have increased the 
popularity of this technology. Tablet disintegration time can be optimized by 
concentrating the disintegrants. Below critical concentration, tablet disintegration time is 
inversely proportional to disintegrants concentration. Above the critical concentration 
level, however, disintegration time remains approximately constant or even increases.  
 Microcrystalline cellulose, cross linked carboxymethyl cellulose sodium, cross 
linked polyvinyl pyrrolidone and partially substituted hydroxypropyl cellulose, though 
water insoluble, absorb water and swell due to capillary action and are considered as 
effective disintegrants in the preparation of dispersible tablets. 
 Fast disintegration of tablets can also be achieved by incorporating effervescent 
disintegrating agents, which generates carbon dioxide. This phenomenon also resulted in 
partial taste masking of unacceptable taste of the drug. The major drawback of 
effervescent excipients is their hygroscopicity (i.e., the ability to absorb atmospheric 
moisture). Hence, their manufacture requires control of humidity conditions and 
protection of the final product. This is reflected by the overall cost of the product.  
 2) Sugar-based excipients: The alternative approach for the development of 
dispersible tablets by direct compression is the use of sugar-based excipients (e.g. 
dextrose, fructose, isomalt, maltose, mannitol, sorbitol, starch hydrolyse, polydextrose, 
and xylitol), which display high aqueous solubility and sweetness, and hence, impart taste 
masking and a pleasing mouth feel.  
Wet granulation 
 The concept of wet granulation is well-known and conventional process for tablet 
formation, used to reduced bitterness of active drug with water insoluble materials. In a 
wet granulation, the material to be granulated, usually in powder forms, is wetted with an 
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aqueous composition of a granulating agent to cause the powdered material to 
agglomerates. This agglomerated product is subsequently dried and then milled to 
reduced size in suitable form. 
 Wet granulation is often carried out utilizing a high-shear mixer. The high-
shear granulation process is a rapid process which is susceptible for over-wetting. Thus, 
the liquid amount added is critical and the optimal amount is affected by the properties of 
the raw materials. Power consumption of the impeller motor and the impeller torque have 
been applied to monitor the rheological properties of the wet mass during agglomeration 
and, thereby, have been used to determine the end-point of water addition. However, 
these methods are affected by the equipment variables. Hence, additional process 
monitoring techniques would be valuable. 
                                      
            
 
 
 
                   
Figure 1: Process principle for formation of agglomerates 
 Wet granulation is often carried out utilizing a high-shear mixer. The high-
shear granulation process is a rapid process which is susceptible for over-wetting. Thus, 
the liquid amount added is critical and the optimal amount is affected by the properties of 
the raw materials. Power consumption of the impeller motor and the impeller torque have 
been applied to monitor the rheological properties of the wet mass during agglomeration 
and, thereby, have been used to determine the end-point of water addition. However, 
these methods are affected by the equipment variables. Hence, additional process 
monitoring techniques would be valuable. 
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Important steps involved in wet granulation 
 Mixing of drug(s) and excipients. 
 Preparation of binder solution. 
 Mixing of binder solution with powder mixture to form wet mass. 
 Coarse screening of wet mass using a suitable sieve (6-12 screens). 
 Drying of moist granules. 
 Screening of dry granules through a suitable sieve (14-20 screens). 
 Mixing of screened granules with disintegrant, glidant, and lubricant. 
Limitations of wet granulation 
 The greatest disadvantage of wet granulation is its cost. It is an expensive 
process because of labor, time, equipment, energy and space requirements. 
 Loss of material during various stages of processing. 
 Stability may be a major concern for moisture sensitive or thermo labile drugs. 
 Multiple processing steps give complexity and make validation and control 
difficult. 
 An inherent limitation of wet granulation is that any incompatibility between 
formulation components is aggravated. 
Spray drying
 
Spray drying is used in pharmaceutical industries to produce highly porous powders. The 
processing solvent is evaporated rapidly by spray drying, which renders the product 
highly porous and thus can be used in manufacturing dispersible tablets. In this 
technique, gelatin can be used as a supporting agent and as a matrix, mannitol as a 
bulking agent and sodium starch glycolate or croscarmellose sodium or crospovidone are 
used as superdisintegrants. Tablets manufactured from the spray dried powder have been 
reported to disintegrate in less than 20 sec in aqueous medium. 
 
Sublimation 
 The key to rapid disintegration for dispersible tablets is the presence of a porous 
structure in the tablet matrix. Conventional compressed tablets that contain highly water-
soluble ingredients often fall to dissolve rapidly because of low porosity of the matrix. 
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Hence, to generate porous matrix, volatile ingredients are used that are later subjected to 
a process of sublimation. e.g. ammonium bicarbonate, ammonium carbonate, benzoic 
acid, camphor, hexamethonium tetramine, naphthalene, phthalic anhydride, urea, and 
urethane were compressed along with other excipients into a table. The volatile material 
was then removed by sublimation, leaving behind a porous matrix. Solvents such as 
cyclohexane and benzene were also suggested for the generation of porosity in the 
matrix. 
Taste masking 
 Taste masking is an essential requirement for fast dissolving tablets for 
commercial success. Taste masking of the active ingredients can be achieved by various 
techniques.  Drugs with unacceptable bitter taste can be microencapsulated into pH 
sensitive acrylic polymers.  Cefuroxime axetil is microencapsulated in various types of 
acrylic polymers (e.g. Eudragit E, Eudragit L-55 and Eudragit RL) by solvent 
evaporation and solvent extraction techniques. These polymer microspheres showed 
efficient taste masking and complete dissolution in a short period. Fine granules of drug 
and disintegrant (e.g. low substituted hydroxypropyl cellulose) when coated with a water 
insoluble polymer (e.g. ethylcellulose) masked the bitter taste of sparfloxacin. The 
addition of low substituted hydroxypropyl cellulose as disintegrant to the drug in cores 
resulted in increased dissolution rate and bioavailability of sparfloxacin compared to its 
conventional tablets.  
Mass extrusion 
 This technology involves softening the active blend using the solvent mixture of 
water soluble polyethylene glycol, using methanol and expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product into even segments using 
heated blade to form tablets. The dried cylinder can also be used to coat granules of bitter 
tasting drugs and thereby masking their bitter taste.  
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 Role of Superdisintegrants in the manufacturing of dispersible tablets 
 Disintegrating agents are substances routinely included in tablet formulations and 
in some hard shell capsule formulations to promote moisture penetration and dispersion 
of the matrix of the dosage form in dissolution fluids. An oral solid dosage form should 
ideally disperse into the primary particles from which it was prepared. Although various 
compounds have been proposed and evaluated as disintegrants, relatively few are in 
common usage today. Traditionally, starch has been the disintegrant of choice in tablet 
formulations, and it is still widely used. For instance, starch generally has to be present at 
levels greater than 5 % to adversely affect compactibility, especially in direct 
compression. Moreover, intragranular starch in wet granulations is not as effective as dry 
starch. 
Mechanism of Superdisintegrants 
There are four major mechanisms for tablets disintegration as follows 
 Swelling 
Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling. Tablets with high porosity show poor disintegration due 
to lack of adequate swelling force. On the other hand, sufficient swelling force is 
exerted in the tablet with low porosity. It is worthwhile to note that if the packing 
fraction is very high, fluid is unable to penetrate in the tablet and disintegration is 
again slows down. 
 Porosity and capillary action (Wicking) 
Disintegration by capillary action is always the first step. When we put the tablet 
into suitable aqueous medium, the medium penetrates into the tablet and replaces 
the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilicity of the drug/excipient and on tableting conditions. For these types of 
disintegrants maintenance of porous structure and low interfacial tension towards 
aqueous fluid is necessary which helps in disintegration by creating a hydrophilic 
network around the drug particles. 
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 Due to disintegrating particle/particle repulsive forces 
Another mechanism of disintegration attempts to explain the swelling of tablet 
made with ‘nonswellable’ disintegrants. Guyot-Hermann has proposed a particle 
repulsion theory based on the observation that nonswelling particle also cause 
disintegration of tablets. The electric repulsive forces between particles are the 
mechanism of disintegration and water is required for it. Researchers found that 
repulsion is secondary to wicking. 
 Due to deformation 
During tablet compression, disintegrated particles get deformed and these 
deformed particles get into their normal structure when they come in contact with 
aqueous media or water. Occasionally, the swelling capacity of starch was 
improved when granules were extensively deformed during compression. This 
increase in size of the deformed particles produces a breakup of the tablet.  
 
Method of Addition of Disintegrants 
 The ideal disintegrant should have the following characteristics: 
 Poor solubility  
 Poor gel formation  
 Good hydration capacity  
 Good molding and flow properties  
 No tendency to form complexes with the drugs  
 Disintegrants are essentially added to tablet granulation for causing the 
compressed tablet to break or disintegrate when placed in aqueous environment. There 
are two methods of incorporating disintegrating agents into the tablet:  
 Internal Addition (Intragranular)  
 External Addition (Extragranular)  
 Partly Internal and External  
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 In external addition method, the disintegrant is added to the sized granulation with 
mixing prior to compression. In Internal addition method, the disintegrant is mixed with 
other powders before wetting the powder mixtures with the granulating fluid. Thus the 
disintegrant is incorporated within the granules. When these methods are used, part of 
disintegrant can be added internally and part externally. This provides immediate 
disruption of the tablet into previously compressed granules while the disintegrating 
agent within the granules produces further erosion of the granules to the original powder 
particles. The two step method usually produces better and more complete disintegration 
than the usual method of adding the disintegrant to the granulation surface only.  
Factors affecting action of disintegrants  
 Percentage of disintegrants present in the tablets.  
 Types of substances present in the tablets.  
 Combination of disintegrants.  
 Presence of surfactants.  
 Hardness of the tablets.  
 Nature of Drug substances. 
 Mixing and Screening.  
 Because of the increased demands for improved dissolution requirements, there 
are currently, a new generation of “Superdisintegrants”. These newer substances are 
more effective at lower concentrations with greater disintegrating efficiency and 
mechanical strength. On contact with water the superdisintegrants swell, hydrate, 
change volume or form and produce a disruptive change in the tablet. Effective 
superdisintegrants provide improved compressibility, compatibility and have no 
negative impact on the mechanical strength of formulations containing high-dose drugs. 
They are widely used in wet granulation and direct compression applications. 
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Classification of superdisintegrants 
Structural type                  
(NF name) 
Description 
Trade name 
(manufacturer) 
Modified starches (Sodium 
starch glycolate, NF) 
Sodium carboxymethyl 
starch; the carboxymethyl 
groups induces 
hydrophilicity and cross-
linking reduces solubility. 
Explotab®(Edward Mendell 
Co.), Primojel® 
(Generichem Corp.), 
Tablo® (Blanver, Brazil) 
Modified cellulose 
(Croscarmellose, NF) 
Sodium carboxymethyl 
cellulose which has been 
cross-linked to render the 
material insoluble. 
AcDiSol® (FMC Corp.), 
Nymcel ZSX® (Nyma, 
Netherlands), Primellose® 
(Avebe, Netherlands) 
Solutab® (Blanver, Brazil) 
Cross-linked poly-
vinylpyrrolidone 
(Crospovidone, NF) 
Cross-linked 
polyvinylpyrrolidone; the 
high molecular weight and 
cross-linking render the 
material insoluble in water. 
Crospovidone M® (BASF 
Corp.), Kollidon CL® 
(BASF Corp.), 
Polyplasdone XL (ISP 
Corp.) 
 
 Three  major groups of compounds have been developed which swell to many 
times their original size when placed in water while producing minimal viscosity 
effects.
19
 
1. Modified starches - Sodium Carboxymethyl Starch (Chemically treated Potato Starch) 
i.e. Sodium Starch Glycolate (Explotab, Primogel) 
Mechanism of Action: Rapid and extensive swelling with minimal gelling. 
Effective Concentration: 4-6 %. Above 8 %, disintegration times may actually increase 
due to gelling and its subsequent viscosity producing effects. 
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2.Cross-linked polyvinylpyrrolidone - water insoluble and strongly hydrophilic. 
i.e. Crospovidone (Polyplasdone XL, Kollidon CL) 
Mechanism of Action: Water wicking, swelling and possibly some deformation recovery.  
Effective Concentration: 2-4 % 
3.Modified cellulose- Internally cross-linked form of Sodium carboxymethyl cellulose. 
i.e. Ac-Di-Sol (Accelerates Dissolution), Nymcel 
Mechanism of Action: Wicking due to fibrous structure, swelling with minimal gelling. 
Effective Concentration: 1-3 % (Direct Compression), 2-4 % (Wet Granulation). 
Advantages 
 Effective in lower concentrations than starch.  
 Less effect on compressibility and flow ability.  
 More effective intragranularly. 
Disadvantages 
 More hygroscopic (may be a problem with moisture sensitive drugs). 
 Some are anionic and may cause some slight in vitro binding with cationic drugs 
(not a problem in vivo). 
Packaging of dispersible tablets 
 Some of the dispersible tablets  are stable during storage, e.g. for 2 years or even 
3 years in conventional packaging and these type of dosage forms are stored in HDPE 
bottles, blister and strip packs. 
Some of the examples of dispersible tablets 
 Aspirin dispersible tablet 
 Cefadroxil dispersible tablet 
 Fast dispersible Ibuprofen  tablet 
 Piroxicam dispersible tablet 
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 Cefpodoxime Proxetil dispersible tablet 
 Cefixime dispersible Tablet  
 Rifampicin and Isoniazid dispersible tablets 
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LITERATURE REVIEW 
 
 
 By Suresh Bandari et al. (2008) 2 Review article:  Oral drug delivery 
remains the preferred route for administration of various drugs. Recent 
developments in the technology have prompted scientists to develop orally 
disintegrating tablets (ODTs) with improved patient compliance and 
convenience. ODTs are solid unit dosage forms which disintegrate or 
dissolve rapidly in the mouth without chewing and water. It describes the 
various formulation aspects, disintegrants employed and technologies 
developed for ODTs, along with various excipients, evaluation tests, 
marketed formulations, and drugs explored in this field.  
 
 C.Mallikarjuna setty et al. (Apr 2008) 15 Development of fast dispersible 
aceclofenac tablets: effect of functionally of super disintegrants. 
Disintegration time and dissolution parameters decreased with increase in the 
level of croscarmellose sodium.  
 
 D M Patel et al. (Feb 2008) 14 The purpose of thes investigation was to 
develop fast dissolving tablets of Etoricoxib. Granules containing Etoricoxib, 
menthol, crospovidone, aspartame and mannitol were prepared by wet 
granulation technique. Menthol was sublimed from the granules by exposing 
the granules to vaccum. The porous granules were then compressed in to 
tablets. The tablets were evaluated for percentage friability and disintegration 
time.  Optimization of fast dissolving Etoricoxib tablets prepared by 
sublimation technique. The dissolving tablets with improved etoricoxib 
dissolution could be prepared by sublimation of tablet containing suitable 
subliming agent.  
 
 Shailesh shatma et al. (Jan 2008) 11 Fast dissolving tablets (FDT) 
promethazine theoclate were   prepared by direct compression method after 
incorporating superdisintegrants Ac-Di-Sol, SSG and Crospovidone in 
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different concentrations. Formulation and characterization of fast-dissolving 
tablets of promethazine theoclate with USP type-II apparatus. 
 
 S.Jacob et al. (Oct 2007) 13 Novel co-processed excipients of mannitol and 
microcrystalline cellulose for preparing fast dissolving tablets of glipizide 
Using spray dring technique. Improves the fast dissolving tablet could be 
prepared by the co-processed mixture of microcrystalline cellulose and 
mannitol. 
 
 Sheetal malke et al. (Apr 2007) 12 Formulation and evaluation of 
oxcarbazepine fast dissolving tablets.  It prepared with Avicel 102 as diluent 
& Ac-Di-Sol as a superdisintegrants by wet granulation process. All the 
formulations were evaluated for characteristics such as Hardness, Friability, 
Weight variation, Wetting ability, Disintegration time and Dissolution rate. A 
modified disintegration method was used for studying disintegration. Since 
the drug is poorly water soluble, drug release was tested in various media and 
effect of surfactant on drug release was studied. 
 
 Jack Y. Zheng et al23 developed the purpose of this study is to assess the 
feasibility for taste masking and comparison of taste intensity during 
formulation development using a multichannel taste sensor system (e-
Tongue). Taste-masking efficiency was evaluated using quinine as a bitter 
model compound and a sweetener, acesulfame K, as a bitterness inhibitor. the 
bitterness inhibition of quinine by using other known taste-masking 
excipients including sodium acetate, NaCl, Prosweet
®
 flavor, and 
Debittering
®
 powder or soft drinks could be detected by the e-Tongue. These 
results further suggest that the e-Tongue should be useful in a taste-masking 
evaluation study on selecting appropriate taste-masking excipients for a 
solution formulation or a reconstitution vehicle for a drug-in-bottle 
formulation. Based on the group distance, the relative intensity of bitterness 
for these compounds could be ranked in the following order: ranitidine 
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HCl > prednisoloneNa > quinine HCl phenylthiourea > paracetamol 
 sucrose  octaacetate > caffeine. In conclusion, the multichannel taste sensor 
or e-Tongue may be a useful tool to evaluate taste-masking efficiency for 
solution formulations and to compare bitterness intensity of formulations and 
drug substances during pharmaceutical product development. 
 
 Omaima A. Sammour et.al (2006)16 investigate the increase in the solubility 
and dissolution rate of Rofecoxib by the preparation of its solid dispersion 
with PVP K -30(1:9) using Solvent evaporation method.  In an attempt to 
construct a statistical model for the prediction of disintegration time and 
percentage friability 3
2 
 randomized full and reduced factorial design was 
used.  The obtained results showed that dispersion of the drug in the polymer 
considerably enhanced the dissolution rate. 
 
 Mishra D.N. et.al.(2005)17 Carried out formulation of rapidly disintegrating 
tablets of  meloxicam  using super disintegrates like   sodium starch 
glycolate, Ac-di-sol and Low molecular weight HPMC.  The disintegration 
time in the oral cavity was tested And was found to be around 1 minute.  It 
was concluded that rapidly disintegrating  tablets with proper hardness 
rapidly disintegrates in the oral cavity with enhanced  Dissolution rate. 
 
 Sheftell FD et.al (2005)18  developed fast disintegrating / Rapid – release 
Formulation of Sumatriptan to enhance tablet disintegration and drug 
dispersion and potentially, improve absorption.  Two studies were conducted 
comparing the time to onset of relief from moderate or severe migraine pain 
with the fast disintegrating / Rapid Release Formulation of Sumatriptan 
tablets 50 and 100 mg and placebo. Using a personal digital assistant, 
patients recorded the time of dosing and the at which pain severity reached 
none that or mild in real time so that the time to onset of relief could be 
measured as a continuous variable.  Results shown that Sumatriptan tablets in 
a fast disintegrating / Rapid release formulation were effective for the acute 
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treatment of moderate to severe migraine pain, were generally well tolerated 
and achieved an onset of pain relief as early as 20 min. for - 100 mg and as 
early as 30 min.for 50 mg. 
 
 Mukesh G. et.al. (2004)19  Formulates mouth dissolving tablet of 
Nimesulide. Granules containing Nimesulide, camphor, crospovidone and 
lactose were prepared by wet Direct Compression technique.  Camphor was 
sublimed from the dried granules by exposure by vacuum.  The porous 
granules were then compressed and evaluated.  The result for obtaining a 
rapidly disintegrating dosage forms, tablets should be prepared using an 
optimum concentration of camphor and a higher percentage of crospovidone. 
 
 Yourong Fu et.al (2004)20 conducted comprehensive review of current 
technologies in making fast dissolving tablet.  Mannose was chosen as the 
best candidate for the investigation.  The mechanisms of fast dissolution of 
mannose tablets were studied.  The strength of mannose tablets was 
improved by the moisture treatment process.  Poly (acrylic acid),   super 
porous hydrogel (SPH) particles showed a high swelling property in various 
aqueous solutions and had a very good compressibility and compatibility.  
The effect of SPH particles on disintegration time and hardness of fast 
dissolving tablet were compared to common super disintegrates such as 
sodium starch glycolate and carboxymethyl cellulose sodium.  The addition 
of SPH significantly decreased the disintegration time of FDT.S but had a 
negative impact on tensile strength.  The results indicates PAA SPH is a 
promising super – disintegrates for making FDT’S. 
 
 Mishra et al21 assessed the suitability of spray dried excipient base in the 
formulation of oral disintegrating tablets of valdecoxib and metoclopramide. 
Superdisintegrants (such as Ac-Di-Sol, Kollidon CL, sodium starch 
glycolate), diluent (mannitol) along with sweetening agent (aspartame) were 
used in the formulation of tablets. Using the same excipients, the tablets were 
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prepared by direct compression and were evaluated in the similar way. 
Maximum drug release and minimum disintegrating time were observed with 
Kollidon CL excipient base as compared to tablets prepared by direct 
compression, showing the superiority of the spray dried excipient base 
technique over direct compression technique 
 
 Moen and Keating et al22 developed a new fast-disintegrating sumatriptan 
tablet with the goal of speeding absorption and onset of effect compared with 
standard sumatriptan tablets. Compared with placebo, pain relief was 
significantly greater with sumatriptan fast disintegrating tablets 100mg at 25 
and 17 minutes following administration and with sumatriptan fast 
disintegrating tablets 50mg at 50 and 30 minutes following administration, to 
severe migraine. 
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AIM AND OBJECTIVE 
 The aim is to develop and formulate PREDNISOLONE SODIUM 
PHOSPHATE Orally Disintegrating tablets using different concentrations of taste 
masking and enteric coating materials comparable to the innovator product with 
better stability,high product feasibility,and excellent patient compatability.  
 The Objective of present study is to mask the bitter taste of the API and 
prepare a Orally disintegrating tablets using taste masking materials, enteric 
coating materials and super disintegrants which is pharmaceutically equivalent to 
the Innovator product. 
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PLAN OF WORK 
 
 To carry out a brief literature review. 
 To do Pre-formulation studies:  
1) API- Tap density, bulk density, angle of repose and compressibility index.   
2) BLEND- Tap density, bulk density, angle of repose and compressibility 
index. 
 To Formulate of PREDISOLONE Sodium Phosphate Orally Disintegrated 
Tablets. 
 To Evaluate PREDISOLONE Sodium Phosphate Orally Disintegrated 
Tablets for Disintegration time and Dissolution study.  
 Selection of best formulation on the basis of Disintegration time and In-vitro 
drug release. 
 To compare the best formulation with that of the innovator. 
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MATERIALS AND METHODS 
 
INSTRUMENT LIST. 
 
Instruments Supplier/Manufacturer 
Compression machine Rimek minipress 
Hot air oven Eltek motors, Mumbai 
RMG mixer Sreenex machines pvt. Limited, Hyderabad 
Sieves Jayanth test sieves. Mumbai. 
Balances Citizen scale pvt. Limited, Thane. 
Density tester Electrolab ,Mumbai 
Disintegration apparatus Electrolab, Mumbai 
Dissolution apparatus Electrolab, Mumbai 
HPLC Waters India pvt. limited, 
Hardness tester Dr.Schleuniger pharmatron,U S A. 
Friabilator Electrolab, Mumbai 
Helium lamp (LOD) Metteler- Toledo 
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MATERIALS LIST. 
 
Materials Supplier/Manufacturer 
Prednisolone sodium phosphate IPCA Laboratories 
Avicel PH101 FMC Polymers 
Poly ethylene Glycol 4000 BASF Corporation 
Ethyl cellulose 4CPS The DOW chemical company 
Mannitol spray dried SPI polyol, 321, new castle. 
Eudragit EPO M/s. DEGUSSA 
Eudragit L100 M/s. DEGUSSA 
Crospovidone XL-10 M/s. ISP Technologies 
Ethyl cellulose The DOW chemical company 
Aspartame Neutrasweet  pharma agencies 
Sodium Bicarbonate Merk Chemicals 
Citric acid Merk Chemicals 
Aerosil M/s. DEGUSSA 
Mint flavors Pan aroma, Chennai 
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METHODS 
 
Innovator Product details: 
Innovator product details including their manufacturer name, description, physical 
parameters and dissolution profile were given in the following table 
Innovator Product details: 
Name of the product ORAPRED – 30mg 
Manufacturer name Alliant Pharmaceuticals Alpharetta, GA 
30022,USA. 
Color White 
Description white, flat faced, beveled tablets, debossed with 
ORA on one side and 30 on the other. 
Package They are supplied as 48 tablets per carton. Each 
carton has 8 cards containing 6 tablets. 
 
Physical parameters of Innovator product: 
 
Parameters 30mg 
Weight of the tablet (mg) 605 
Thickness (mm) 5.14 
Hardness (kp) 3.08 
Disintegration time (sec) 26 
Dispersion time (sec) 60 
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PREFORMULATION STUDIES
6
: 
Drug-excipient compatibility studies: 
 The proper design and the formulation of a dosage form require consideration 
of the physical, chemical and biological characteristics of the drug and 
excipients used in fabricating the product. The drug and excipients must be 
compatible with one another to produce a product that is stable, efficacious, 
attractive, easy to administer and safe. 
 The compatibility studies provide the framework for the drugs combination 
with excipients in the fabrication of the dosage form. The study was carried 
out to establish that the therapeutically active drug has not undergone any 
changes, after it has been subjected to processing steps during formulation of 
tablets. 
 Compatibility studies were carried out by mixing definite proportions of drug 
and excipient and kept in glass vials, which are stored at 55°C (2 weeks) and 
40±2°C/75±5 % RH(4 weeks). 
Physical parameters of blend: 
             The following evaluation parameters studies were performed for the 
Prednisolone sodium Phosphate. 
 
Sieve Analysis: 
Pass a define mass of the sample through various sieves and calculate the 
percentage of retained powder and fines passed through sieves. 
                                                                     Weight of the powder 
  Percentage of powder retained = ----------------------------------- X 100 
                                                                   Total weight of the powder 
Bulk density: 
             It is the ratio between a given mass of powder and its bulk volume. 
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        Mass of powder 
    Bulk density = ----------------------------------- 
                                   Total weight of the powder        
 
A given quantity of the powder is transferred to the measuring cylinder and it 
is tapped mechanically either manually or mechanical device till a constant volume is 
obtained. This volume is bulk volume (v) and it includes the true volume of the 
powder and void space among the powder particles. 
 
Angle of repose: 
 
 Angle of repose is defined as the maximum angle possible between the 
surface of pile of powder and the horizontal plane. The granule mass should allowed 
to flow out of the funnel orifice on a plane paper kept on the horizontal surface. This 
forms a pile of granules on the paper.      
 
                   Tan θ = h/r                  θ = tan-1(h/r) 
    Where, h= height of the pile 
                 r= radius of the pile 
 
Tapped density: 
  
 Tapped density is defined as the ratio between weight of the sample powder 
taken and the tapped volume.  
    
               Tapped density(ρt) = M/Vf 
 
Where , M  = weight of sample powder taken 
              Vf   = tapped volume 
 
Compressibility index /Carr’s index: 
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Based on the apparent bulk density and the tapped density, the percentage 
compressibility index of the powder was determined by using the following formula. 
 
      Tapped density-Bulk density 
                       Compressibility index =    -----------------------------------------   X 100 
       Tapped density 
 
Hausner ratio: 
 
By calculating tapped density and bulk density, the Hausner ratio can be 
calculated. 
               Hausner ratio = ρt  / ρo 
  Where,  ρt = tapped density 
                ρo = bulk density 
Flow Properties of Powder. 
S. No Angle of repose Carr’s index 
Hausner’s 
ratio 
Properties 
1 25-30 5-12 1.00-1.11 Free Flowing 
2 30-35 12-16 1.12-1.18 Good 
3 35-40 18-21 1.19-1.25 Fair 
4 40-55 23-35 1.35-1.45 Poor 
5 55-65 33-38 1.46-1.59 Very poor 
6 >65 >40 >1.60 Extremely poor 
 
There are various in-process control parameters should be performed. They are 
During tablet compression:      
o Appearance 
o Average weight 
o Weight uniformity 
o Hardness 
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o Thickness 
o Disintegration time  
o Dissolution8    
 
Method development: 
Formulation of Prednisolone orally disintegrating tablets by method of taste 
masking with PEG 4000, Ethyl cellulose, Eudragit EPO and Eudragit L100. Tablets 
can be formulated by wet granulation method. 
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DRUG PROFILE 
 
PREDNISOLONE SODIUM PHOSHATE 
Chemical name: pregna-1, 4-diene-3,20-dione,11, 17-dihydroxy-21-
(phosphonooxy),  disodium salt(11ß)- 
. 
The empirical formula:  C21H27Na2O8P;  
The molecular weight: 484.39 
Physical properties 
Color: White or slightly yellowish 
State/form: Friable granules or powder 
Solubility: It is freely soluble in water; soluble in methanol; slightly soluble in 
alcohol and in chloroform; and very slightly soluble in acetone and in dioxane. 
Pharmacokinetics: 
Absorption: Absorbed from GIT 
Bioavailability: Found to be about 62%. The fraction of the dose recovered in the 
urine as the hydroxylated metabolites of prednisone and prednisolone was lower after 
the oral prednisone dose, suggesting that poor absorption of prednisone was the main 
cause of the low bioavailability.  
Plasma binding: 70-90% 
Elimination: Eliminated from the plasma with a half-life of 2 to 4 hours. It is 
metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide 
conjugates.  
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Dose: Available in strengths containing 13.4 mg, 20.2 mg, and 40.3 mg prednisolone 
sodium phosphate (equivalent to 10 mg, 15 mg, or 30 mg prednisolone base, 
respectively). 
Pharmacodynamics: 
Pharmacological Category: Glucocorticoid  
 
Clinical Pharmacology
4
: 
Naturally occurring glucocorticoids (hydrocortisone), which also have salt-
retaining properties, are used as replacement therapy in adrenocortical deficiency 
states. Their synthetic analogs are primarily used for their potent anti-inflammatory 
effects in disorders of many organ systems.  
 
Prednisolone is a synthetic adrenocortical steroid drug with predominantly 
glucocorticoid properties. Some of these properties reproduce the physiological 
actions of endogenous glucocorticosteroids, but others do not necessarily reflect any 
of the adrenal hormones normal functions; they are seen only after administration of 
large therapeutic doses of the drug. The pharmacological effects of prednisolone 
which are due to its glucocorticoid properties include: promotion of gluconeogenesis; 
increased deposition of glycogen in the liver; inhibition of the utilization of glucose; 
anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation 
of fat synthesis and storage; increased glomerular filtration rate and resulting increase 
in urinary excretion of urate (creatinine excretion remains unchanged); and increased 
calcium excretion.  
 
Depressed production of eosinophils and lymphocytes occurs, but 
erythropoiesis and production of polymorphonuclear leukocytes are stimulated. 
Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of 
leukocytes and phagocytosis) and the later stages of wound healing (capillary 
proliferation, deposition of collagen, cicatrization) are inhibited.  
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Prednisolone can stimulate secretion of various components of gastric juice. 
Suppression of the production of corticotropin may lead to suppression of 
endogenous corticosteroids. Prednisolone has slight mineralocorticoid activity, 
whereby entry of sodium into cells and loss of intracellular potassium is stimulated. 
This is particularly evident in the kidney, where rapid ion exchange leads to sodium 
retention and hypertension.  
  
 Prednisolone is rapidly and well absorbed from the gastrointestinal tract 
following oral administration. Prednisolone is 70-90% protein-bound in the plasma 
and it is eliminated from the plasma with a half-life of 2 to 4 hours. It is metabolized 
mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates.  
 
The systemic availability, metabolism and elimination of prednisolone after 
administration of single weight-based doses (0.8 mg/kg) of intravenous (IV) 
prednisolone and oral prednisone were reported in a small study of 19 young (23 to 
34 years) and 12 elderly (65 to 89 years) subjects. Results showed that the systemic 
availability of total and unbound prednisolone, as well as interconversion between 
prednisolone and prednisone were independent of age. The mean unbound fraction of 
prednisolone was higher, and the steady-state volume of distribution (Vss) of 
unbound prednisolone was reduced in elderly patients. Plasma prednisolone 
concentrations were higher in elderly subjects, and the higher AUCs of total and 
unbound prednisolone were most likely reflective of an impaired metabolic clearance, 
evidenced by reduced fractional urinary clearance of 6b-hydroxyprednisolone. 
Despite these findings of higher total and unbound prednisolone concentrations, 
elderly subjects had higher AUCs of cortisol, suggesting that the elderly population is 
less sensitive to suppression of endogenous cortisol or their capacity for hepatic 
inactivation of cortisol is diminished.  
 
Oral administration of single doses of 30 mg prednisolone base equivalent of 
Orapred ODT and Pediapred Solution to 21 adult volunteers yielded comparable 
pharmacokinetic data:  
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Dose* 
(30 mg prednisolone base 
equivalent) 
AUC0- 
(nghr/mL) 
(S.D.) 
Cmax 
(nghr/mL)** 
(S.D.) 
Pediapred Solution 2426.1 (360.0) 461.33 (77.94) 
Orapred ODT 2408.1 (361.5) 420.91 (78.28) 
 
*Administered under fasting conditions.  
**Mean values of 21 normal volunteers. 
 
 USES: It is used for treatment of severe inflammatory conditions including 
allergies, arthritis, asthma, or skin reactions. It may also be used to treat certain blood, 
adrenal gland, eye, respiratory, or bowel conditions. It may also be used for other 
conditions as determined by your doctor. Orapred ODT is a corticosteroid. It works 
by modifying the body's immune response to various conditions and decreasing 
inflammation. 
 
HOW TO USE: This medication is dissolved in the mouth on top of the tongue. It 
may also be swallowed whole with water.  
Side Effects: 
 
(Listed alphabetically under each subsection):  
Cardiovascular: Hypertrophic cardiomyopathy in premature infants.  
Dermatologic: Facial erythema; increased sweating; impaired wound healing; may 
suppress reactions to skin tests; petechiae and ecchymoses; thin fragile skin; urticaria; 
edema.  
 
Endocrine: Decreased carbohydrate tolerance; development of cushingoid state; 
hirsutism; increased requirements for insulin or oral hypoglycemic agents in diabetic 
patients; manifestations of latent diabetes mellitus; menstrual irregularities; secondary 
adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in 
trauma, surgery or illness; suppression of growth in children.  
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Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients; 
fluid retention; hypertension; hypokalemic alkalosis; potassium loss; sodium 
retention.  
Gastrointestinal: Abdominal distention; elevation in serum liver enzyme levels 
(usually reversible upon discontinuation); pancreatitis; peptic ulcer with possible 
perforation and hemorrhage; ulcerative esophagitis.  
Metabolic: Negative nitrogen balance due to protein catabolism.  
Musculoskeletal: Aseptic necrosis of femoral and humeral heads; loss of muscle 
mass; muscle weakness; osteoporosis; pathologic fracture of long bones; steroid 
myopathy; tendon rupture; vertebral compression fractures.  
 
Neurological: Convulsions; headache; increased intracranial pressure with 
papilledema (pseudotumor cerebri) usually following discontinuation of treatment; 
psychic disorders; vertigo.  
Ophthalmic: Exophthalmos; glaucoma; increased intraocular pressure; posterior 
subcapsular cataracts. 
Contraindications: 
Systemic fungal infections, hypersensitivity to the drug or any of its components 
Drug Interactions: 
Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce 
hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of 
prednisolone and require that the dosage of Orapred be increased.  
 
Increased activity of both cyclosporin and corticosteroids may occur when the 
two are used concurrently. Convulsions have been reported with this concurrent use.  
  
 Estrogens may decrease the hepatic metabolism of certain corticosteroids 
thereby increasing their effect.  
 
Ketoconazole has been reported to decrease the metabolism of certain 
corticosteroids by up to 60% leading to an increased risk of corticosteroid side 
effects.  
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Co administration of corticosteroids and warfarin usually results in inhibition 
of response to warfarin, although there have been some conflicting reports. Therefore, 
coagulation indices should be monitored frequently to maintain the desired 
anticoagulant effect.  
 
Concomitant use of aspirin (or other non-steroidal anti-inflammatory agents) 
and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should 
be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The 
clearance of salicylates may be increased with concurrent use of corticosteroids.  
 
When corticosteroids are administered concomitantly with potassium-
depleting agents (i.e., diuretics, amphotericin-B), patients should be observed closely 
for development of hypokalemia. Patients on digitalis glycosides may be at increased 
risk of arrhythmias due to hypokalemia.  
 
Concomitant use of anticholinesterase agents and corticosteroids may produce 
severe weakness in patients with myasthenia gravis. If possible, anticholinesterase 
agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.  
 
Due to inhibition of antibody response, patients on prolonged corticosteroid 
therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. 
Corticosteroids may also potentiate the replication of some organisms contained in 
live attenuated vaccines. If possible, routine administration of vaccines or toxoids 
should be deferred until corticosteroid therapy is discontinued.  
 
Because corticosteroids may increase blood glucose concentrations, dosage 
adjustments of antidiabetic agents may be required.  
Corticosteroids may suppress reactions to skin tests.  
 
STORAGE: Store at room temperature between 68-77 degrees F (20-25 degrees C) 
away from light and moisture. Keep all medicines away from children and pets.  
 
  Drug profile  
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           49 
LIST OF EXCIPIENTS USED 
 
POLYETHYLENE GLYCOL 
Nonproprietary Names:   
BP: Macrogol 400 
   JP :  Macrogol 400 
Macrogol 1500  
Macrogol 4000 
Macrogol 6000 
Macrogol 20000 
PhEur:   Macrogola 
USPNF:   Polyethylene glycol 
Synonyms: Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; 
polyoxyethylene glycol. 
Chemical Name and CAS Registry Number: α-Hydro-ω-hydroxypoly (oxy-1, 2-
ethanediyl) [25322-68-3] 
Empirical Formula and Molecular Weight: HOCH2(CH2OCH2)mCH2OH where m 
represents the average number of oxyethylene groups. Alternatively, the general 
formula H(OCH2CH2)nOH may be used to represent polyethylene glycol, where n is a 
number m in the previous formula + 1. 
Structural formula and molecular weight of typical polyethylene glycol 
polymers: 
 
Grade m Average molecular weight 
PEG 200 4.2 190–210 
PEG 300 6.4 285–315 
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Grade m Average molecular weight 
PEG 400 8.7 380–420 
PEG 540 (blend) — 500–600 
PEG 600 13.2 570–613 
PEG 900 15.3 855–900 
PEG 1000 22.3 950–1 050 
PEG 1450 32.5 1 300–1 600 
PEG 1540 28.0–36.0 1 300–1 600 
PEG 2000 40.0–50.0 1 800–2 200 
PEG 3000 60.0–75.0 2 700–3 300 
PEG 3350 75.7 3 000–3 700 
PEG 4000 69.0–84.0 3 000–4 800 
PEG 4600 104.1 4 400–4 800 
PEG 8000 181.4 7 000–9 000 
 
Structural Formula: 
 
 
Functional Category: 
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Ointment base; plasticizer; solvent; suppository base; tablet and capsule 
lubricant 
Applications in Pharmaceutical Formulation or Technology: 
Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical 
formulations including parenteral, topical, ophthalmic, oral, and rectal preparations. It 
has been used experimentally in biodegradable polymeric matrices used in controlled-
release systems. 
 
In solid-dosage formulations, higher-molecular-weight polyethylene glycols 
can enhance the effectiveness of tablet binders and impart plasticity to granules. 
However, they have only limited binding action when used alone, and can prolong 
disintegration if present in concentrations greater than 5% w/w. When used for 
thermoplastic granulations, a mixture of the powdered constituents with 10–15% w/w 
PEG 6000 is heated to 70–75°C. The mass becomes paste like and forms granules if 
stirred while cooling. This technique is useful for the preparation of dosage forms 
such as lozenges when prolonged disintegration is required. 
 
In film coatings, solid grades of polyethylene glycol can be used alone for the 
film-coating of tablets or can be useful as hydrophilic polishing materials. Solid 
grades are also widely used as plasticizers in conjunction with film-forming 
polymers. Polyethylene glycols are useful as plasticizers in microencapsulated 
products to avoid rupture of the coating film when the microcapsules are compressed 
into tablets. 
 
Description: 
The USPNF 23 describes polyethylene glycol as being an addition polymer of 
ethylene oxide and water. Polyethylene glycol grades 200–600 are liquids; grades 
1000 and above are solids at ambient temperatures. 
 
Liquid grades (PEG 200–600) occur as clear, colorless or slightly yellow-
colored, viscous liquids. They have a slight but characteristic odor and a bitter, 
slightly burning taste. PEG 600 can occur as a solid at ambient temperatures. 
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Solid grades (PEG>1000) are white or off-white in color, and range in 
consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of 
PEG 6000 and above are available as free-flowing milled powders. 
 
Solubility: 
 All grades of polyethylene glycol are soluble in water and miscible in all 
proportions with other polyethylene glycols (after melting, if necessary). Aqueous 
solutions of higher-molecular-weight grades may form gels.  
  
 Liquid polyethylene glycols are soluble in acetone, alcohols, benzene, 
glycerin, and glycols. Solid polyethylene glycols are soluble in acetone, 
dichloromethane, ethanol (95%), and methanol; they are slightly soluble in aliphatic 
hydrocarbons and ether, but insoluble in fats, fixed oils, and mineral oil. 
 
ETHYLCELLULOSE 
 
Nonproprietary Names:  
BP: Ethyl cellulose 
PhEur: Ethylcellulosum 
USPNF: Ethylcellulose 
 
Synonyms: Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
 
Chemical Name: Cellulose ethyl ether  
 
CAS Registry Number: [9004-57-3] 
 
Empirical Formula and Molecular Weight: Ethylcellulose with complete 
ethoxyl substitution (DS = 3) is C12H23O6 (C12H22O5) nC12H23O5 where n can 
vary to provide a wide variety of molecular weight. 
 
Functional Category: Coating agent; flavoring fixative; tablet binder; tablet 
filler; viscosity-increasing agent. 
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Applications in Pharmaceutical Formulation or Technology: 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations 
 
Use Concentration (%): 
 Microencapsulation 10.0–20.0 
 Sustained-release tablet coating 3.0–20.0 
 Tablet coating 1.0–3.0 
 Tablet granulation 1.0–3.0 
 
 The main use of ethylcellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. 
  
 Ethylcellulose coatings are used to modify the release of a drug, to mask an 
unpleasant taste, or to improve the stability of a formulation; for example, where 
granules are coated with ethylcellulose to inhibit oxidation.  
 
 Modified-release tablet formulations may also be produced using 
ethylcellulose as a matrix former. Higher-viscosity ethylcellulose grades tend to 
produce stronger and more durable films.  
 
 In topical formulations, ethylcellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. 
 Ethylcellulose has been studied as a stabilizer for emulsions. 
 Ethylcellulose is additionally used in cosmetics and food products. 
 
Description: 
Ethylcellulose is a tasteless, free-flowing, and white to light tan-colored 
powder. 
 
Solubility: 
 
 Ethylcellulose is practically insoluble in glycerin, propylene glycol, and water. 
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
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chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of aromatic 
hydrocarbons with ethanol (95%). 
 
Ethylcellulose that contains not less than 46.5% of ethoxyl groups is freely 
soluble in chloroform, ethanol (95%), ethyl acetate, methanol, and toluene. 
 
POLYMETHACRYLATES 
Nonproprietary Names: 
BP: Methacrylic acid–ethyl acrylate copolymer (1: 1) 
PhEur: Acidum methacrylicum ethylis acrylas polymerisatum 1: 1 
USPNF: Ammonio methacrylate copolymer,Methacrylic acid copolymer, 
Methacrylic acid copolymer dispersion 
 
Synonyms: Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit; Kollicoat MAE 
30 D; Kollicoat MAE 30 DP; polymeric methacrylates.  
 
Chemical Name, Trade Name and CAS Registry Number: 
 Poly (methacrylic acid, methyl methacrylate) 1: 1 Eudragit L100 [25806-15-
1] 
 Poly(butyl methacrylate, (2-dimethylaminoethyl)methacrylate, methyl 
methacrylate) 1 : 2 : 1 Eudragit E100,Eudragit E12.5,Eudragit EPO [24938-
16-7]. 
 
Empirical Formula and Molecular Weight: 
 Eudragit L100 :Methacrylic acid–methyl methacrylate copolymer (1 : 1) is 
described in the PhEur 2005 as a copolymer of methacrylic acid and methyl 
methacrylate having a mean relative molecular mass of about 135 000. 
 Eudragit EPO: The ratio of (2-dimethylaminoethyl) methacrylate groups to 
butyl methyacrylate and methyl methacrylate groups is about 2: 1: 1. 
Polyacrylate dispersion (30 per cent) is described in the PhEur 2005 as a 
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dispersion in water of a copolymer of ethyl acrylate and methyl methacrylate 
having a mean relative molecular mass of about 800 000. 
 
Structural Formula: 
 
Functional Category: Film former; tablet binder; tablet diluent 
Applications in Pharmaceutical Formulation or Technology. 
 
Type  
 
Supply 
form 
Polymer 
dry 
weight 
content 
 
 
Recommended 
solvents or 
diluents 
 
Solubility/permeabi
lity 
Applications 
 
Eudragit 
E12.5 
 
 
Organic 
solution 
 
12.5% Acetone, 
alcohols 
Soluble in gastric 
fluid 
to pH 5 
 
Film coating 
 
Eudragit 
EPO 
 
Powder   
 
98% Acetone, 
alcohols 
Soluble in gastric 
fluid 
to pH 5 
 
Film coating 
 
Eudragit 
L100 
 
Powder 95% Acetone, 
alcohols 
 
Soluble in intestinal 
fluid from pH 6 
 
Enteric 
coatings 
 
Eudragit 
L100-55 
Powder 95% Acetone, 
alcohols 
Soluble in intestinal 
fluid from pH 5.5 
Enteric 
coatings 
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Eudragit 
S100 
 
Powder 95% Acetone, 
alcohols 
 
Soluble in intestinal 
fluid from pH 7 
 
Enteric 
coatings 
 
Eudragit 
RL 100 
 
Granules 97% Acetone, 
alcohols 
 
High permeability Sustained 
release 
 
 
Description: 
 
 Polymethacrylates are synthetic cationic and anionic polymers of 
dimethylaminoethylmethacrylates, methacrylic acid, and methacrylic acid esters in 
varying ratios. Severaldifferent types are commercially available and may be obtained 
as the dry powder, as anaqueous dispersion, or as an organic solution. A (60: 40) 
mixture of acetone and propan-2-olis is most commonly used as the organic solvent. 
 
Solubility:  
 
Solubility of commercially available polymethacrylates in various solvents. 
 
Type 
 
Acetone 
and 
alcohols 
Dichloro-
methane 
Ethyl 
acetate 
 
1 N 
HCl 
 
1 N 
NaOH 
 
Petroleum 
Ether 
Water 
 
Eudragit 
E12.5 
 
M M M M — M — 
Eudragit 
S 
100 
 
S 
 
I I — S I I 
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Eudragit 
L 
100 
 
S I I — S I I 
Eudragit 
RL 
100 
 
S 
 
S S — — I I 
S = soluble; M = miscible; I = insoluble or immiscible; P = precipitates. 
MANNITOL 
Nonproprietary Names: 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitolum 
USP: Mannitol 
 
Synonyms: Cordycepic acid; C*PharmMannidex; E421; manna sugar; D-mannite; 
mannite; Mannogem; Pearlitol. 
 
Chemical Name and CAS Registry Number: D-Mannitol [69-65-8] 
Empirical Formula and Molecular Weight:  C6H14O6 182.17 
Structural Formula: 
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Functional Category:   
Diluent; diluent for lyophilized preparations; sweetening agent; tablet and 
capsule diluent; tonicity agent 
 
Applications in Pharmaceutical Formulation or Technology: 
 
 Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in tablet 
formulations, where it is of particular value since it is not hygroscopic and may thus 
be used with moisture-sensitive active ingredients.  
 
 Mannitol may be used in direct-compression tablet applications, for which the 
granular and spray-dried forms are available, or in wet granulations. Granulations 
containing mannitol have the advantage of being dried easily. Specific tablet 
applications include antacid preparations, glyceryl trinitrate tablets, and vitamin 
preparations.  
 
Mannitol is commonly used as an excipient in the manufacture of chewable 
tablet formulations because of its negative heat of solution, sweetness, and ‘mouth 
feel’.  
 
Description: 
 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is 
isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or 
free-flowing granules. It has a sweet taste, approximately as sweet as glucose and half 
as sweet as sucrose, and imparts a cooling sensation in the mouth. 
Solubility of Mannitol. 
Solvent Solubility at 20°C 
Alkalis Soluble 
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Solvent Solubility at 20°C 
Ethanol (95%) 1 in 83 
Ether Practically insoluble 
Glycerin 1 in 18 
Propan-2-ol 1 in 100 
Water 1 in 5.5 
 
MICROCRYSTALLINE CELLULOSE 
                                
Nonproprietary names:   
BP: Microcrystalline cellulose (MCC) 
JP: Microcrystalline cellulose 
Ph Eur: Cellulosum microcrystallinum 
USPNF: Microcrystalline cellulose 
 
Synonyms:   Avicel PH; Celex; Cellulose gel; Celphere;    Ceolus KG; 
Crystalline cellulose; E460; Emcocel; Ethisphere; Fibro- cel; Pharmacel; Tabulose 
                                                   . 
Chemical name: Cellulose  
Empirical formula: C 6H10O5)n    Where n=220         
Molecular weight: 36000        
 
Functional category: Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrating agent. 
 
Applications in Pharmaceutical Technology: 
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MCC is widely used in pharmaceuticals primarily as a binder /Diluent in oral 
tablet and capsule formulations where it is used in both wet granulation and direct 
compression processes. (20-90%) 
 
It also has some lubricant and disintegrating properties.   (5-15%).   
It is used in cosmetics and food products. 
 
Description:  
 MCC is purified, partially depolymerized cellulose that occurs as a white, 
odorless, tasteless, crystalline powder composed of porous particles. Commercially 
available  in different particle sizes and moisture grades that have different properties 
and applications. 
 
Solubility:  
 
Slightly soluble in 5%w/v sodium hydroxide solution. Practically insoluble in 
water, dilute acids and most organic solvents. 
 
CROSPOVIDONE 
 
Nonproprietary names:  
BP: Crospovidone 
Ph Eur: Crospovidonum 
USPNF: Crospovidone 
 
Synonyms: Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; 
Polyplasdone XL; Polyplasdone XL-10;  
Chemical name: 1- Ethenyl-2-pyrrolidinone homopolymer 
Emperical formula: (C6H9NO) n    
Molecular weight: >1000000. 
 
Functional category: Tablet disintegrant 
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Applications in Pharmaceutical Technology: 
1) Crospovidone is a water insoluble tablet disintegrant and dissolution 
agent used at 2-5%conc in tablets prepared by direct compression or dry 
granulation method. 
 2) It rapidly exhibits high capillary activity and pronounced hydration 
capacity, with little tendency to form gels. 
 3) Studies suggest that particle size of crospovidone strongly influences 
disintegration of analgesic tablets. Larger particles provide a faster 
disintegration than smaller particles. 
  4) Crospovidone can be used as a solubility enhancer. With the technique 
of co-evaporation, crospovidone can be used to enhance the solubility of 
poorly soluble drugs.  
 
Description: Crospovidone is a white to creamy white, finely divided free-Flowing, 
practically tasteless, and odorless or nearly odorless, hygroscopic powder. 
 
Solubility: Practically insoluble in water and most organic solvents. 
ASPARTAME  
Nonproprietary names:  
BP: Aspartame 
Ph Eur: Aspartamum  
USPNF: Aspartame                                           
 
Synonyms: 3-Amino-N-(α-carboxyphenethyl) succinamic acid N-methyl ester; 3-
Amino-N-(α- methoxycarbonyl phenethyl) succinamic acid; Aspartyl pheylamine 
methyl ester; Canderel; E 951; Equal; Methyl N-α-L-aspartyl-L- phenylalaninate; 
Nutrasweet; Sanecta; SC-18862; Tri-sweet. 
 
Chemical name: N-α-L-Aspartyl-L-phenylalanine 1-methyl ester. 
Emperical formula: C14H18N2O5        
Molecular weight: 294.31 
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Functional category: Sweetening agent 
 
Applications in Pharmaceutical Technology: 
 
 Aspartame is used as an intense sweetening agent in beverage products, food 
products, table top sweeteners and in pharmaceutical preparations including tablets, 
powder mixes and vitamin preparations. 
 It enhances flavor systems and can be used to mask some unpleasant taste 
characteristics; the approximate sweetening power is 180-200 times that of sucrose. 
 Therapeutically, aspartame is used in the treatment of sickle cell anemia. 
 
Description: Aspartame occurs as an off white, almost odorless crystalline powder 
with an intensely sweet taste. 
 
 
Solubility:  Slightly soluble in ethanol (95%), sparingly soluble in water. At 20
0
C the 
solubility is 1%w/v at the isoelectric point (pH 5.2). Solubility increases at higher 
temperatures and at more acidic pH, e.g. At pH 2 and 20
0
C solubility is 10%w/v. 
 
SODIUM BICARBONATE 
Nonproprietary Names: 
BP: Sodium bicarbonate 
JP: Sodium bicarbonate 
PhEur: Natrii hydrogenocarbonas 
USP: Sodium bicarbonate 
 
Synonyms: Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; 
sodium acid carbonate; sodium hydrogen carbonate. 
 
Chemical Name and CAS Registry Number: 
Carbonic acid monosodium salt [144-55-8] 
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Empirical Formula and Molecular Weight: NaHCO3 84.01 
Structural Formula:  NaHCO3 
Functional Category: Alkalizing agent; therapeutic agent 
 
Applications in Pharmaceutical Formulation or Technology: 
 
Sodium bicarbonate is generally used in pharmaceutical formulations as a 
source of carbon dioxide in effervescent tablets and granules. It is also widely used to 
produce or maintain an alkaline pH in a preparation. 
 
In effervescent tablets and granules, sodium bicarbonate is usually formulated 
with citric and/or tartaric acid;  
 
When the tablets or granules come into contact with water, a chemical 
reaction occurs, carbon dioxide is evolved, and the product disintegrates. Melt 
granulation in a fluidized bed dryer has been suggested as a one-step method for the 
manufacture of effervescent granules composed of anhydrous citric acid and sodium 
bicarbonate, for subsequent compression into tablets. 
Uses of sodium bicarbonate. 
 
Use Concentration (%) 
Buffer in tablets 10–40 
Effervescent tablets 25–50 
Isotonic injection/infusion 1.39 
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Solubility of sodium bicarbonate. 
 
Solvent Solubility at 20°C unless otherwise stated 
Ethanol (95%) Practically insoluble 
Ether Practically insoluble 
Water 1 in 11 
 1 in 4 at 100°C
a
 
 1 in 10 at 25°C 
 1 in 12 at 18°C 
 
 
CITRIC ACID MONOHYDRATE 
Nonproprietary Names: 
BP: Citric acid monohydrate 
JP: Citric acid 
PhEur: Acidum citricum monohydricum 
USP: Citric acid 
 
Synonyms: E330; 2-hydroxypropane-1,2,3-tricarboxylic acid monohydrate. 
Chemical Name and CAS Registry Number: 
2-Hydroxy-1,2,3-propanetricarboxylic acid monohydrate [5949-29-1] 
 
Empirical Formula and Molecular Weight: C6H8O7·H2O 210.14 
Structural Formula: 
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Functional Category: 
 
Acidifying agent; antioxidant; buffering agent; chelating agent; flavor 
enhancer. 
 
Applications in Pharmaceutical Formulation or Technology: 
 
Citric acid (as either the monohydrate or anhydrous material) is widely used in 
pharmaceutical formulations and food products, primarily to adjust the pH of 
solutions.  
It has also been used experimentally to adjust the pH of tablet matrices in enteric-
coated formulations for colon-specific drug delivery  
Citric acid monohydrate is used in the preparation of effervescent granules, 
while anhydrous citric acid is widely used in the preparation of effervescent tablets.  
 
Description: 
Citric acid monohydrate occurs as colorless or translucent crystals, or as a 
white crystalline, efflorescent powder. It is odorless and has a strong acidic taste. The 
crystal structure is orthorhombic. 
 
Solubility: 
 
Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of water; 
sparingly soluble in ether. 
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COLLOIDAL SILICON DIOXIDE 
              
Nonproprietary names: BP: Colloidal anhydrous silica 
Ph Eur: Silica colloidalis anhydrica 
USPNF: Colloidal Silicon Dioxide 
Synonyms: Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; Colloidal silica; Fumed silica 
light anhydrous silicic acid; Silicic anhydride; Silicon dioxide fumed; Wacker HDK. 
Chemical name: Silica 
Empirical formula: SiO2                    
Molecular weight: 60.08 
 
Functional category: Adsorbent; anti-caking agent; emulsion stabilizer; glidant; 
Suspending agent; tablet disintegrant; thermal stabilizer; viscosity increasing agent. 
 
Applications in Pharmaceutical Technology:-  
 It is used in pharmaceuticals, cosmetics and food products. 
 It is used to stabilize emulsions and as a thixotropic thickening and 
suspending agent in gels and semisolid preparations. 
 It is used to promote particulate suspension, eliminate, hard settling, and 
minimize the clogging of spray nozzles. 
 It is used as a tablet disintegrant and as an adsorbent dispersing agent for 
liquids in powders. 
 
Solubility:  Practically insoluble in organic solvents, water and acids except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide forms a colloidal 
dispersion with water. 
 
MAGNESIUM STEARATE 
Nonproprietary names: BP: Magnesium Stearate                                                                                                                
                                             JP: Magnesium Stearate 
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                                             Ph Eur: Magnesii stearas 
                                             USPNF: Magnesium Stearate  
 
 Synonyms: Magnesium octadecananoate; Octadecanoic acid; Magnesium salt; 
stearic acid magnesium salt. 
 
Chemical name: Octadecanoic acid magnesium salt 
Emperical formula: C36H70MgO4          
Molecular weight: 591.34 
Functional category: Tablet and capsule lubricant. 
 
Applications in Pharmaceutical Technology:- 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25 and 5%w/w. 
It is also used in barrier creams. 
 
Description: Magnesium stearate is a fine, white, precipitated or milled, Impalpable 
powder of low bulk density, having a faint odor or and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
 
Solubility:  Practically insoluble in ethanol, ethanol(95%), ether and water, 
slightly soluble in warm benzene and warm ethanol(95%). 
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RESULTS: 
Drug- Compatibility Studies: 
S.No Ingredients Ratio Description 
Initial    55°C         
(2 weeks) 
40±2°C /75±5 % 
RH   (4 weeks) 
1 API 1 White  No change No change 
2 Avicel PH101 1 White No change No change 
3 Crospovidone XL 1 White No change No change 
4 Starch 1500 1 White No change No change 
5 Etyl Cellulose 
4CPS 
1 white No change No change 
6 PEG4000 1 Off white No change No change 
7 Ethyl cellulose 
EPO 
1 white No change No change 
8 Mannozem 1 White No change No change 
9 Magnesium stearate 1 White No change No change 
10 Eudragit 1 White No change No change 
11 Eudragit L100 1 White No change No change 
12 Aerosil 1 white No change No change 
13 Aspartame 1 Off white No change No change 
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14 Sodiumbicarbonate 1 White No change No change 
15 Citric Acid 1 White No change No change 
16 Mint Flavours 1 Off white No change No change 
17 API+ Crospovidone 
XL 
5:1 White No change No change 
18 API+ Starch 1500 5:1 White No change No change 
19 API+ MCC PH 101 1:5 Off white No change No change 
20 API+PEG4000 5:1 Off white No change No change 
21 API+ EC 4CPS 5:1 Off white No change No change 
22 API+ Aerosil 5:1 White No change No change 
23 API+ MS 5:1 Off white No change No change 
24 API+EC EPO 5:1 Off white No change No change 
25 API+Mannozem 5:1 Off white No change No change 
26 API+Eudragit EPO 5:1 White No change No change 
27 API+Eudragit L100 5:1 Off white No change No change 
28 API+Aspartame 5:1 Off white No change No change 
29 API+SB 5:1 Off white No change No change 
30 API+ Citric Acid 5:1 Off white No change No change 
31 API+ Mint 5:1 White No change No change 
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Physical Parameters of API. 
 
S.No. 
 
Test 
 
Specifications 
 
Results 
 
1. 
 
Description 
 
Off-white to beige colored 
powder. 
 
Complies 
 
2. 
 
Solubility 
 
Soluble in water, slightly 
soluble in chloroform. 
 
Complies 
 
3. 
 
Identification: 
IR-Spectrum 
 
IR-Spectrum of the test 
sample should match with the 
IR-Spectrum of the working 
standard. 
 
Complies 
 
4. 
 
Loss on Drying 
(at 105
 º
C for 3hrs) 
 
 
0.14% w/w 
 
 0.5% w/w 
 
5. 
 
Residue on ignition 
 
0.04% w/w 
 
 0.1% w/w 
 
6. 
 
Related substances 
(by HPLC) 
Impurity-A 
Impurity-B 
Any other impurity 
Total Impurities 
 
 
 
Not detected 
Not detected 
0.09% 
0.19% 
 
 
 
0.15 
0.15 
0.10 
1.00 
 
7. 
 
Assay 
 
99.9% w/w 
 
98.0% w/w & 102.0% w/w. 
calculated on dried substance. 
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*[Impurity-A: 3-(2-Chloroethyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4H pyrido 
(1,2-a)pyrimidine-4-one. 
    Impurity-B: 6-fluoro-3-piperidin-4-yl-1,2-benzisoxazloe. 
 
PARTICLE SIZE ANALYSIS. 
S.No. ASTM 
Weight of 
mesh(A) 
Weight of mesh+Powder 
(B) 
B-A %Retained 
1 100 331.9 349.2 17.3 57.66 
2 140 325.8 332.2 6.4 21.33 
3 200 324.1 326.4 2.3 7.66 
4 Collector 539.9 543.9 4.0 13.33 
Total    30.0 99.98 
 
*Note: Powder taken = 30 gms. 
 
 
DRUG SOLUBILITY STUDY (pH 1-7). 
S.No. Medium Percentage Mg/ml 
 
1 
 
D.M.Water 
 
100.9% 
 
0.37 
 
2 
 
0.1N HCl 
 
101.5% 
 
0.37 
 
3 
 
4.5 Acetate buffer 
 
100.1% 
 
0.36 
 
4 
 
6.8 Phosphate buffer 
 
100.1% 
 
0.36 
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pH: 
60 mg of API in 50 ml of DM Water. 
    pH of API    =  7.92 
2 Tablets in 50 ml of DM Water. 
    pH of tablets    = 6.12 
Innovators 2 Tablets in 50 ml of DM Water. 
    pH of tablets     = 6.65 
 
Density: 
Initial weight = 25.9 gms 
Initial volume = 88 ml 
Tapped density = 0.728 gm/ml 
Bulk density  = 0.521 gm/ml 
Compressibility 
 Index  = 28.40 % 
Hausner Ratio = 1.397 
 
Dissolution parameters: 
Apparatus  : USP2, Paddle. 
Medium  : 22M sodium acetate buffer, pH.4.5. 
Medium volume : 500 ml. 
Medium Temp : 37 ±0.5 
º
C. 
Paddle speed  : 50 rpm. 
Sampling Time   : 60 min 
Sampling Time  
Points (profile) : 5, 15, 30, 40, 60 min. 
Sampling volume : 5 ml 
 
Chromatographic conditions for Dissolution and Assay: 
Column  : Kromosil C18, (150×4.6mm), 5µm. 
Flow rate  : 1.0ml/min 
Wave length  : UV-254 
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Column Temperature: 30°C 
Injection volume : 20µl 
Run time  : 15min 
 
UNITARY FORMULA 
Label claim: Each tablet contains: Prednisolone sodium phosphate 42.98mg 
Equivalent to Prednisolone 30mg. 
Materials Percentage in a tablet Function 
Prednisolone sodium phosphate 7.16 Active Pharmaceutical Ingredient 
Avicel PH101 33.33 Diluent 
Poly ethylene Glycol 4000 7.16 Taste masking agent 
Ethyl cellulose 4CPS 7.16 Taste masking agent 
Ethyl cellulose 2.5 Taste masking agent 
Mannozem EZ 
(Mannitol spray dried) 
20.55 Sweetener 
Eudragit EPO 3.58 Taste masking agent 
Eudragit L100 3.58 Taste masking agent 
Crospovidone XL-10 12.50 Disintegrant 
Aspartame 4.16 Sweetener 
Sodium Bicarbonate 2.66 Alkalizing agent  
Citric acid 2.08 Buffering agent 
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Magnesium stearate 1.90 Lubricant 
Aerosil 0.47 Glident 
Mint flavors 0.83 Flavor 
 
formulation 1:- For 1000 Tablets. 
Preparation of drug-stearic acid solution: 
Weigh accurately the required quantity of API and dissolve in 129ml of water. 
Weigh accurately the required quantity of Stearic acid and dissolve in 200ml of IPA. 
Then mix drug solution to stearic acid solution. Solubilise with continuous stirring for 
homogenous mixing for 20min. 
Granulation: 
 Weigh Mannozem EZ, Crosspovidone XL, Avicel pH101, and Starch1500. 
Then sift all the ingredients through 30# mesh. Take all ingredients in a bowl and 
then granulate with the help of drug-stearic acid solution to form a damp mass. Then 
granules are kept for drying until dried. Dried granules are passed through 35# mesh. 
 Weigh Sodium bicarbonate, Citric acid, Aspartame, Mint flavor, Aerosil, 
Sodium stearyl fumarate are pass through 35# mesh and mix to the granules, one by 
one in a continuous manner. Mix the blend continuously for 3min.  
Observation: 
 Powder taste is bitter. 
Formulation 2:- For 200 Tablets. 
Weigh accurately the required quantity of Ethylcellulose and add 20gms of 
IPA, stir for 45min, by using mechanical stirrer to get clear solution. Weigh 
accurately the required quantity of API and dissolve in required quantity (25ml) of 
water to get clear solution. Weigh accurately Avicel pH101 and passed through 40#  
  Drug Profile  
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           75 
FORMULATION OF PREDNISOLONE ODT ( 30mg ) 
  Intragranulation (mg/tab) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
API 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 42.98 
Poly Ethylene Glycol 4000 __ 
__ __ __ 
40 40 42.98 42.98 42.98 42.98 42.98 42.98 __ 
Ethyl cellulose 4cps 
__ __ __ __ __ __ __ 
25 
__ __ 
40 __ 42.98 
Purified water Q.S. Q.S. Q.S. __ Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. __ 
Ethyl cellulose __ 10 __ 12 15 
__ __ __ __ __ __ __ __ 
Isopropyl alcohol Q.S. Q.S. 
__ __ 
Q.S. Q.S. 
__ __ __ __ 
Q.S. __ Q.S. 
Methylene chloride 
__ __ __ __ 
Q.S. Q.S. 
__ __ __ __ __ __ __ 
MCC (Avicel pH101) 100 250 250 248 245 245 225 230 230 230 230 230 200 
Aspartame 
__ __ __ __ __ __ 
10 10 10 10 10 10 10 
Mannozem. EZ 
(spray dried mannitol) 
244.02 
__ __ __ __ __ 
60 60 60 60 60 60 __ 
Eudragit L100 
__ __ __ __ __ __ __ __ 
21.49 14.32 __ 21.49 21.49 
Eudragit EPO 
__ __ 
42.98 
__ __ 
42.98 42.98  21.49 28.64 40 21.49 21.49 
Isopropyl alcohol 
__ __ 
Q.S. Q.S. 
__ 
Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. 
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Acetone 
__ __ 
Q.S. Q.S. 
__ 
Q.S. Q.S. __ Q.S. Q.S. Q.S. Q.S. Q.S. 
Stearic acid 40 
__ __ __ __ __ __ __ __ __ __ __ __ 
Starch 1500 40 
__ __ __ __ __ __ __ __ __ __ __ __ 
Crosspovidone XL 60 
__ __ __ __ __ __ __ __ __ __ __ __ 
            Extra Granulation (mg/tab) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
Mannozem. EZ 
(spray dried mannitol) 
__ 
182.25 152.29 182.25 137.27 109.29 56.31 69.13 51.40 51.40 14.29 33.31 123.31 
Crosspovidone XL 10 
__ 
57 57 57 57 57 57 57 57 57 57 75 75 
Sodium bicarbonate 15 16 16 16 16 16 16 16 16 16 16 16 16 
Citric acid 20 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
Aspartame 18 10 10 10 15 15 15 15 15 15 15 15 15 
Mint flavor 2 5 2 5 5 5 5 5 5 5 5 5 5 
75 
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Aerosil 
(colloidal silicon dioxide) 
6 2.85 2.85 2.85 2.85 2.85 2.85 2.85 2.85 2.85 2.85 2.85 2.85 
Magnesium stearate __ 11.40 11.40 11.40 11.40 11.40 11.40 11.40 11.40 11.40 11.40 11.40 11.40 
Sodium stearyl fumarate 12 
__ __ __ __ __ __ __ __ __ __ __ __ 
Total(mg) 600 600 600 599.98 600 600 600 599.84 600 600 600 600 600 
 
 
 
76 
  Drug Profile  
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           78 
mesh. And granulate with drug solution to get a wet mass. The wet mass is 
dried in tray drier at 60
º
C. 
After 15 min the same wet mass was again granulated with ethyl cellulose 
solution. The wet mass was passed through 10# mesh and dried at 40
º
C. The dried 
granules are passed through 20# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and pass through 40# mesh. Add to the dried granules and 
mix for 5min. Weigh accurately Magnesium stearate, Aerosil and pass through 40# 
mesh, and add to the above blend and lubricate for 2min. 
Observation: 
 Powder taste is bitter. 
Formulation 3:- For 500 Tablets.        
Weigh accurately the required quantity of API and dissolve in required 
quantity (63ml) of water to get clear solution. Weigh accurately Eudragit EPO are 
add to the mixture of (1:1) IPA and Acetone, stir for 45min using mechanical stirrer 
to get clear solution. 
Weigh accurately Avicel pH101 and pass through 40# mesh. Granulate with 
drug solution to get a wet mass. The wet mass is dried in tray drier at 60
º
C. 
Semi-dried granules are granulating with Eudragit EPO solution. The wet 
mass is passed through 10# mesh and dried at 45
º
C. The dried granules are passed 
through 18# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and pass through 40# mesh. Add to the dried granules and 
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mix for 5min. Weigh accurately Magnesium stearate, Aerosil and pass through 40# 
mesh, and add to the above blend and lubricate for 2min. 
Observation: 
 After taste is bitter 
Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 4:- For 200 Tablets. 
Weigh accurately the required quantity of Ethylcellulose and add to the 
20gms of IPA, stir for 45min, by using mechanical stirrer to get clear solution. Weigh 
accurately the required quantity of API and dissolve in required quantity (63ml) of 
water to get clear solution. 
Weigh accurately Avicel pH101 and pass through 40# mesh. Granulate with 
drug solution to get a wet mass. The wet mass is dried in tray drier at 60
º
C. Semi-
dried granules are granulated with Ethyl cellulose solution. The wet mass passed 
through 12# mesh and dried at 60
º
C. The dried granules are passed through 18# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor, and Aerosil are passed through 40# mesh. And add to the 
dried granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
 After taste is bitter 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 5:- For 200 Tablets. 
Weigh accurately the required quantity of API and dissolve in required 
quantity (25ml) of water to get clear solution. Weigh accurately Avicel pH101 and 
pass through 40# mesh. Granulate with drug solution to get a wet mass. The wet mass 
is dried in tray drier at 55±5
º
C. 
  Weigh accurately PEG4000 and add to the required quantity of mixture of 
IPA and Methylene chloride (1:1) (13:13) solution to get a clear solution. The dried 
granules are granulated with PEG4000 solution. The wet mass is dried in tray drier at 
55±5
º
C. 
The dried granules are passed through 40# mesh. Weigh accurately Ethyl 
cellulose and add to the 20gms of IPA, stir for 45min, by using mechanical stirrer to 
get cleat solution. The above granules are again granulated with Ethyl cellulose 
solution. The wet mass was passed through 12# mesh and dried at 55±5
º
C. 
The dried granules are passed through 18# mesh. Weigh Mannozem EZ, 
Crosspovidone XL10, Sodium bi carbonate, citric acid, Aspartame, Mint flavor, and 
Aerosil and pass through 40# mesh. Add to the dried granules and mixed for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with scale line 
on, one punch was used for compression. 
Formulation 6:- For 200 Tablets. 
Weigh accurately the required quantity of API and dissolve in required 
quantity (25ml) of water to get clear solution. Weigh accurately Avicel pH101 and 
passed through 40# mesh. Granulate with drug solution to get a wet mass. The wet 
mass is dried in tray drier at 55±5
º
C. 
Weigh accurately PEG4000 and add to the required quantity of mixture of 
IPA and Methylene chloride (1:1) (13:13) solution to get a clear solution. The dried 
granules are granulated with PEG4000 solution. The wet mass is dried in tray drier at 
55±5
º
C. 
The dried granules are passed through 40# mesh. Weigh accurately Eudragit 
EPO and add to the mixture of (1:1) IPA and Acetone, stir for 45min using 
mechanical stirrer to get clear solution. The above granules are granulated with 
Eudragit EPO solution. The wet mass was passed through 12# mesh and dried at 
55±5
º
C. The dried granules are passed through 18# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and Aerosil and pass through 40# mesh. Add to the dried 
granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to the 
above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 7:- For 200 Tablets. 
Weigh accurately PEG4000 are added to the required quantity of water 
(45gms). Weigh accurately API and add it to the above solution. Mix for 10min to get 
a clear solution. Weigh Avicel pH101, Mannozem EZ and Aspartame and pass 
through 40# mesh and granulate with the above solution. 
The wet mass was passed through 12# mesh and dried at 55±5
º
C. The dried 
granules are passed through 12# mesh. Weigh accurately Eudragit EPO and add to 
the mixture of (1:1) IPA and Acetone, stir for 30min using mechanical stirrer to get 
clear solution. 
The above granules are granulated with Eudragit EPO solution. The wet mass 
was passed through 12# mesh and dried at 55±5
º
C. The dried granules are passed 
through 40# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor, and Aerosil are passed through 40# mesh and added to the 
dried granules and mixed for 3min. 
Weigh accurately Magnesium stearate and passed through 40# mesh, and 
added to the above blend and lubricated for 2min. 
Observation: 
After taste is bitter. 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 8:- For 200 Tablets. 
Weigh accurately PEG4000 and added to the required quantity of water 
(45gms). Weigh accurately API and add it to the above solution. Mixed for 10min to 
get a clear solution. Weigh Avicel pH101, Mannozem EZ and Aspartame and pass 
through 40# mesh and granulate with the above solution. 
The wet mass was passed through 12# mesh and dried at 55±5
º
C. The dried 
granules are passed through 12# mesh. Weigh accurately Ethylcellulose and add to 
the required quantity of (25gms) IPA. Stir for 45min using mechanical stirrer to get 
clear solution. 
The above granules are again granulated with Ethyl cellulose solution. The 
wet mass passes through 12# mesh and dried at 55±5
º
C. The dried granules are 
passed through 40# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and Aerosil and pass through 40# mesh. Add to the dried 
granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 9 and 12:- For 500 Tablets. 
Weigh accurately PEG4000 and add to the required quantity of water 
(113.75gms). Weigh accurately API and add it to the above solution. Mix for 10min 
to get a clear solution. Weigh Avicel pH101, Mannozem EZ and Aspartame and pass 
through 40# mesh and granulate with the above solution. 
The wet mass was passed through 12# mesh and dried at 60
º
C. The dried 
granules are passed through 30# mesh. 
Weigh accurately Eudragit EPO,Eudragit L100 (1:1) and add to the mixture 
of (1:1) (50:50) IPA and Acetone, stir for 45min using mechanical stirrer to get clear 
solution. The above granules are again granulated with above (step5) solution. The 
wet mass was passed through 12# mesh and dried at 55±5
º
C. The dried granules are 
passed through 30# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and Aerosil and pass through 40# mesh. Add to the dried 
granules and mix for 3min. 
 Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 10:- For 500 Tablets. 
Weigh accurately PEG4000 and add to the required quantity of water 
(113.75gms). Weigh accurately API and add it to the above solution. Mix for 10min 
to get a clear solution. Weigh Avicel pH101, Mannozem EZ and Aspartame and pass 
through 40# mesh and granulate with the above solution. The wet mass was passed 
through 12# mesh and dried at 60
º
C. The dried granules are passed through 30# mesh. 
Weigh accurately Eudragit EPO,Eudragit L100 (2:1) and added to the 
mixture of (1:1) (50:50) IPA and Acetone, stirred for 45min using mechanical stirrer 
to get clear solution. The above granules are again granulated with above (step5) 
solution. The wet mass was passed through 12# mesh and dried at 55±5
º
C. The dried 
granules are passed through 30# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor, and Aerosil and passed through 40# mesh. Add to the dried 
granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
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Formulation 11:- For 500 Tablets. 
Weigh accurately PEG4000 and add to the required quantity of water 
(113.75gms). Weigh accurately API and add it to the above solution. Mix for 10min 
to get a clear solution. Weigh Avicel pH101, Mannozem EZ and Aspartame and pass 
through 40# mesh and granulate with the above solution. The wet mass was passed 
through 12# mesh and dried at 60
º
C. The dried granules are passed through 30# mesh. 
Weigh accurately Ethyl cellulose and add to the required quantity of 
(100gms) IPA and stir for 45min using mechanical stirrer to get clear solution. The 
above granules are again granulated with above solution. The wet mass was passed 
through 12# mesh and dried at 55±5
º
C. The dried granules are passed through 30# 
mesh. 
Weigh accurately Eudragit EPO and add to the mixture of (1:1) IPA and 
Acetone, stir for 45min using mechanical stirrer to get a clear solution. The above 
granules are again granulated with above solution. The wet mass was passed through 
12# mesh and dried at 55±5
º
C. The dried granules are passed through 30# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and Aerosil and pass through 40# mesh. Add to the dried 
granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
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Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
Formulation 13:- For 500 Tablets. 
Weigh accurately Ethyl cellulose and API and pass through 40# mesh and 
mix well. And granulate with required quantity of (17) IPA to get wet mass. The wet 
mass was passed through 12# mesh and dried at 50±5
º
C. The dried granules are 
passed through 30# mesh. Weigh Avicel pH101 and Aspartame are passed through 
40# mesh and add to the above dried granules and mixed for 5min. 
Weigh accurately Eudragit EPO, Eudragit L100 (1:1) and add to the mixture 
of (1:1) (50:50) IPA and Acetone. The above blend is granulated with above solution 
to get wet mass. The wet mass was passed through 12# mesh and dried at 50±5
º
C. 
The dried granules are passed through 30# mesh. 
Weigh Mannozem EZ, Crosspovidone XL10, Sodium bi carbonate, citric acid, 
Aspartame, Mint flavor and Aerosil and pass through 40# mesh. Add to the dried 
granules and mix for 3min. 
Weigh accurately Magnesium stearate and pass through 40# mesh, and add to 
the above blend and lubricate for 2min. 
Observation: 
After taste is bitter. 
Compression: 
Lubricated granules are compressed with 12.5mm round flat punches with 
scale line on, one punch was used for compression. 
  Result   
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           88 
RESULTS AND DISCUSSION 
  
 EVALUATION OF TABLETS:  
 
Formulation Avg.Weights(mg) 
Thickness 
(mm) 
Hardness  
kg/cm
2
) 
 
Friability 
(%) 
Disintigration 
Time (sec) 
F-3 602.6 4.72 4.14 1.43 22 
F-4 602.5 4.72 3.40 1.40 24 
F-5 606.3 4.75 3.90 1.13 40 
F-6 604.1 4.90 3.58 1.00 28 
F-7 604.2 4.88 3.86 1.43 56 
F-8 604.7 3.90 3.98 1.54 45 
F-9 600.3 5.13 3.02 2.08 25 
F-10 601.6 5.13 2.69 1.89 21 
F-11 600 5.11 3.10 2.30 30 
F-12 600.1 5.14 3.11 1.87 26 
F-13 601.9 4.70 4.05 0.72 26 
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Taste evaluation (Palatability study) for formulation containing mint flavor: 
  
S.No. Volunteers AGE SEX 
Patient acceptability (Taste) 
Good Better Average 
1. Volunteer 1 26 M    
2. Volunteer 2 24 F    
3. Volunteer 3 28 M    
4. Volunteer 4 30 M    
5. Volunteer 5 27 F    
6. Volunteer 6 25 M    
7. Volunteer 7 31 M    
8. Volunteer 8 29 M    
9. Volunteer 9 35 M    
10. Volunteer 10 24 F    
        
DISSOLUTION PROFIE OF ORAPRED ODT (30mg) 
Time 
(min) 
%Drug release in 
Water 
Time 
(min) 
%Drug release in 
0.1N HCl 
% Drug release in 
4.5 Acetate buffer 
0 0 0 0 0 
5 36.7 5 47.6 80.9 
10 49.9 15 89.2 97.6 
20 68.5 30 94.4 99.6 
30 71.1 45 95.6 98.6 
45 81.1 60 96.3 99.2 
Assay 88.9  98.6 99.4 
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Figure 1: Dissolution profile of ORAPRED ODT in Water. 
 
 
Figure 2: Dissolution profile of ORAPRED ODT in 0.1N Hcl. 
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Figure 3: Dissolution profile of ORAPRED ODT in 4.5 Acetate buffer. 
 
 
Figure 4: Dissolution profile of ORAPRED ODT in different media. 
 
 
 
Cumulative Percentage Of Drug Release in pH 4.5 Phosphate Buffer. 
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Sampling 
Time 
Cumulative Percentage Of Drug Release in pH 4.5 Phosphate Buffer. 
 
F-3 F-4 F-5 F-6 F-7 F-8 
5 96.3 110.6 103.5 103.5 101.8 99.1 
15 100.1 111.0 105.9 105.9 102.2 99.2 
30 100.8 110.8 106.6 106.6 102.4 106.1 
45 101.3 110.6 107.3 107.3 102.4 106.5 
60 101.2 110.0 107.8 107.8 102.4 107.4 
Assay 100.7 109.7 106.2 101.9 100.6 104.9 
 
 
 
Sampling 
Time 
Cumulative Percentage Of Drug Release in pH 4.5 Phosphate 
Buffer. 
 
F-9 F-10 F-11 F-12 F-13 
5 73.2 74.2 48.5 65.3 60.3 
15 87.4 84.6 76.1 86.7 78.7 
30 91.7 89.8 80.6 92.2 89.1 
45 95.8 95.2 80.6 95.7 92.4 
60 95.0 93.3 87.5 99.4 98.1 
Assay 89.0 88.8 80.1 99.7 99.2 
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Figure 5: Dissolution profile of Formulations F-3, F-4, F-5, and F-6. 
 
 
 
Figure 6: Dissolution profile of Formulations F-7, F-8, F-9, and F-10. 
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Figure 7:  Dissolution profile of Formulations F-11, F-12, and F-13. 
 
 
 
Figure 8: Dissolution profile of   ORPRED and Formulation F-12. 
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DISCUSSION 
 
The present investigation was undertaken to formulate Prednisolone into 
orally disintegrating tablet formulation for the treatment of severe inflammatory 
conditions allergies, arthritis, asthma, or skin reactions. 
 
Wet granulation techniques were used in formulating the drug into orally 
disintegrating tablet. 
  
 All the experimental formulation batches have been subjected to various 
evaluations viz, average weight, friability, disintegration, thickness, hardness, 
dissolution, content uniformity and taste masking. 
 
  Formulation F-1 was made by wet granulation using Drug-stearic acid 
solution and the lubricated blend taste has not met the specifications of ODT. 
 
Formulation F-2 was made by wet granulation using Ethylcellulose(1.66%) in 
Isopropyl alcohol as a taste masking agent and the lubricated blend taste has not met 
the specifications of ODT. 
    
 Formulation F-3 was made by wet granulation using Eudragit EPO (7.16%) 
{in Isopropyl alcohol and acetone (1:1)} as a taste masking agent and the lubricated 
blend had good taste. In this formulation hardness and disintegration gave satisfactory 
results. 
    
 Formulation F-4 was made by wet granulation using Ethylcellulose (2.0%) {in 
Isopropyl alcohol} as a taste masking agent and the lubricated blend after taste was 
bitter. In this formulation hardness and disintegration gave satisfactory results. 
Formulation F-5 was made by wet granulation using PEG4000 (6.66%) {in 
Isopropyl alcohol and methylene chloride} as a taste masking agent, drug has to be 
dissolved in water and granulated with mcc and again granulated it with PEG4000 
solution. 
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And the dried granules were again granulated with Ethylcellulose (2.5%) {in 
Isopropyl alcohol} solution and extra granulation was carried out and the lubricated 
blend after taste was bitter. In this formulation hardness and disintegration gave 
satisfactory results. 
 
Formulation F-6 was made by wet granulation using PEG4000 (6.66%) {in 
Isopropyl alcohol and methylene chloride} as a taste masking agent, API has to be 
dissolve in water and granulate with mcc and again granulate it with PEG4000 
solution. 
 
And the dried granules were again granulated with Eudragit EPO (7.16%) {in 
Isopropyl alcohol and acetone (1:1)} solution and extra granulation was carried out 
and the lubricated blend after taste was bitter. In this formulation hardness and 
disintegration gave satisfactory results. 
 
Formulation F-7 was made by using PEG4000 in required quantity of water 
and API was added to PEG4000 solution granulation was done with mcc, mannitol 
i.e., mannogem EZ and   Aspartame. And granulated with Eudragit EPO (7.16%) {in 
Isopropyl alcohol and acetone (1:1)} solution and extra granulation was carried out 
and the lubricated blend after taste was bitter. In this formulation hardness and 
disintegration gave satisfactory results. 
 
Formulation F-8 was made by replacing Eudragit EPO solution with 
Ethylcellulose 4cps (4.16%) (in Isopropyl alcohol) solution and the remaining 
ingredients are same as formulation F-7.  And the lubricated blend after taste was 
bitter. In this formulation hardness and disintegration gave satisfactory results. 
   
 Formulation F-9, 10 &11 was made by using PEG4000 in water, API  was 
added to it to get a clear solution granulation was done with  mannogem EZ and   
Aspartame. 
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For F-9 granulate the above granules with Eudragit L100 and Eudragit 
EPO(1:1)(3.58:3.58) {in Isopropyl alcohol and acetone (1:1)} solution and extra 
granulation was carried out and the lubricated blend had good taste. In this 
formulation hardness and disintegration gave satisfactory results. 
 
Formulation F-10 granulate the above granules with Eudragit L100 and 
Eudragit EPO(1:2)(4.77:2.38) {in Isopropyl alcohol and acetone (1:1)} solution and 
extra granulation was carried out and the lubricated blend has good taste. In this 
formulation hardness and disintegration gave satisfactory results. 
 
Formulation F-11 granulate the above granules with Ethylcellulose 4cps(6.66) 
in IPA and dried granules were again granulated with Eudragit EPO(6.66) {in 
Isopropyl alcohol and acetone (1:1)} solution and extra granulation was carried out 
and the lubricated blend had good taste. In this formulation hardness and 
disintegration gave satisfactory results. 
 
Formulation F-12 was reproducibility of F-9 Batch with change in percentages 
of mannozem EZ (5.55%) and crosspovidone XL10 (12.5%) and lubricated blend has 
good taste. In this formulation hardness and disintegration gave satisfactory results. 
Formulation F-13 was made by Ethylcellulose4cps and API are mixed and granulated 
with Isopropyl alcohol and after mixing the remaining intra granular ingredients and 
granulating with Eudragit L100 and Eudragit EPO(1:1){in Isopropyl alcohol and 
acetone (1:1)} solution. Extra granulation was carried out and the lubricated blend 
had a good taste. 
 
 
 
 
  Summary And Conclusion 
                                       
Dept of Pharmaceutics, Annai veilankanni’s pharmacy college, chennai           98 
SUMMARY AND CONCLUSION 
 
The demand for orally disintegrating tablets has enormously increased during 
the last decade. Particularly for geriatric and pediatric patients who have difficulty in 
swallowing conventional tablets and capsules. Oral administration of the drugs is 
difficult in patients having concomitant vomiting or diarrhea. Fast dissolving or fast 
disintegrating dosage form is advantageous for such patients. Fast dissolvable or fast 
disintegrating dosage forms are meant to disintegrate immediately upon contact with 
the saliva leading to faster release of drug in the oral cavity. Because administrating 
the fast disintegrating dosage forms, absorption of the drugs occurs through buccal 
mucosa and it may reduce the first pass metabolism leading to better efficacy of the 
drug.  
 
Prednisolone is a naturally occurring glucocorticoids (hydrocortisone), it 
targets to corticosteroid binding globulin (it regulates Enzyme regulatory activity, 
Enzyme inhibitory activity and protease inhibitory activity. Which also have salt-
retaining properties, are used as replacement therapy in adrenocortical deficiency 
states. Their synthetic analogs are primarily used for their potent anti-inflammatory 
effects in disorders of many organ systems. Used in treatment of severe inflammatory 
conditions including allergies, arthritis, asthma, or skin reactions. 
 
 Its metabolizing enzyme is Cytochrome P450 3A4 (CYP 3A40). In present 
work wet granulation technique was employed to prepare tablets. Microcrystalline 
cellulose was used as diluent. Aspartame and mannitol were used as sweetening 
agents.  Crospovidone XL10 as disintegrant. Predinisolone Sodium Phosphate was 
having bitter taste and to mask the bitter taste flavoring agent like mint flavour and 
taste masking agents like PEG4000, Ethylcellulose 4cps, Eudrait EPO and Eudragit 
L100 were used. Post compressional parameters hardness, friability, weight variation, 
disintegration time, drug content and dissolution studies are studies were done. 
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Taste, disintegration and dissolution profiles of best formulations F-12 and F-
13 are better than marketed product  i.e. ORAPRED.  
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